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Background: There are various indications for the use of oral anticoagulants. Two common 
indications are in patients with atrial fibrillation and prosthetic heart valves. The quality of 
anticoagulation, determined by the time in therapeutic range, is less often evaluated and has important 
clinical implications in patient outcomes.  
Objectives: We sought to identify the indications for anticoagulation and determine the time in 
therapeutic range and the time out of range at a community-based and district level in patients 
attending the outpatient department at Mahatma Gandhi Memorial Hospital in KwaZulu Natal, South 
Africa. Further, we identified factors associated with the quality of anticoagulation and identified 
prevalence and contributors to thrombo-embolic and haemorrhagic events in anticoagulated patients 
with atrial fibrillation and prosthetic heart valves.   
Overview of thesis: Chapter 1 is a review of the literature and identifies the objectives of the study. 
Chapter 2 describes the study design and methodology. The sample population is described in Chapter 
3. Chapter 4 and 5 evaluates the time in therapeutic range and Chapter 6 evaluates for associations 
thereof. Chapter 7 describes the findings of adverse events and the final chapter summarises the thesis 
with a general discussion and conclusion. 
Methods: We conducted a retrospective, descriptive and observational study with chart audits 
evaluating the anticoagulation control for the preceding one year for each patient. Descriptive 
statistics included mean and standard deviation for quantitative data and frequencies for categorical 
data. The variables demonstrated uniformity with linear plots and therefore comparisons of means 
was conducted by parametric testing. Analysis of variance was conducted for comparisons of 
variables with post hoc analysis for three groups. Confidence intervals were reported as 95%. Two-
tailed p-values were conducted and any p-value less than .05 was considered significant. 
Results: TTR was poor for patients with atrial fibrillation and prosthetic valves (44.5% and 13.7% 
respectively). We identified older age, less frequent testing and high target ranges as significant 
factors associated with poorer outcomes. We demonstrated a high prevalence of adverse events 
(25.4%). 
Conclusion: Patients in this setting demonstrated poor quality of anticoagulation and had a high 
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INTRODUCTION AND LITERATURE REVIEW 
Warfarin is used as an oral anticoagulant across various conditions in treating and preventing 
thrombosis and embolism, commonly, for atrial fibrillation (AF), prosthetic heart valves and venous 
and arterial thrombo-embolism. Due to its complex pharmacodynamics, there is usually no standard 
dose and therefore requires monitoring to assess its efficacy and reduce the risk of bleeding 
complications. 
 
1.1 Warfarin as an anticoagulation agent 
Warfarin is a vitamin K antagonist (VKA) with excellent bioavailability and is widely prescribed as 
an oral anticoagulant. VKAs produce their anticoagulant effect by interfering with the cyclic 
interconversion of vitamin K and it‟s epoxide which, through a complex pathway leads to the 
depletion of coagulant proteins namely; prothrombin, factor VII, factor IX and factor X. In addition, 
VKAs impair the regulation of the anticoagulant proteins C and S and therefore impair their function. 
Warfarin has two isomers namely R and S which are metabolised in the liver by different pathways. 
The main enzyme involved in the elimination of the S- isomer is the CYP2C9, while the R- isomer of 
warfarin is eliminated by CYP1A/CYP1A2/CYP3A4 
1
. These enzymes may be inhibited or induced 
by drugs taken by the patient and can have effects on the bioavailability of warfarin and subsequently 
affect its efficacy or potentiate its effect as an anticoagulant. 
The efficacy of warfarin as an anticoagulant is best measured by the prothrombin time (PT) which is 
reported as an international normalisation ratio (INR), and is a measure of three of the four vitamin K-
dependant coagulation factors; factor II, factor VII and factor X. The INR is determined by dividing 
the PT of a patient with the geometric mean of the PT of at least 20 healthy subjects of both sexes 
with the same test system. An INR of 1.0 is considered to be normal anticoagulation and an INR of 
2.0 means that the clotting time has doubled 
1
. 
The most important adverse effect of warfarin is the risk of bleeding which is influenced directly by 
the intensity of anticoagulation therapy and higher INR values confer greater risk. The most notable 
non-haemorrhagic adverse event associated with warfarin is skin necrosis. This is uncommon and is 
due to extensive thrombosis of the capillaries and venules in the subcutaneous tissue. 
The use of warfarin as a VKA in clinical practice has many indications (Table 1). The most common 
uses are in the setting of venous or arterial thrombo-embolism or a high risk thereof (as in 
antiphospholipid antibody syndrome). The different indications have individualised target INR ranges 
and duration of therapy. Two notable indications for long-term oral anticoagulation are in the setting 
of non-valvularAF for the prevention of stroke and/or systemic embolisation, and in the presence of 








Table 1: Indications for anticoagulation with warfarin and the recommended target INR 
2
. 
Indication Recommended Target INR 
Venous thrombo-embolism  
First event 2.5 
Recurrence while anticoagulated 
 
3.5 
Antiphospholipid antibody syndrome 2.5 
Atrial fibrillation 2.5 
Elective cardioversion  
At least 3 weeks prior 3.0 
Four weeks after 
 
2.5 
Valvular heart disease and prosthetic valves  
Mitral stenosis or regurgitation
a
 2.5 
Mechanical prosthetic valves  
Low thrombogenicity and no risk factors 2.5 
Low thrombogenicity and risk factors 3.0 
Medium thrombogenicity and no risk factors 3.0 
Medium thrombogenicity and risk factors 3.5 








Myocardial infarction and cardiomyopathy 2.5 
a. Patients with mitral stenosis or regurgitation who haveatrial fibrillation or a history of systemic embolism or 
left atrial thrombus or an enlarged leftatrium should receive warfarin with an INR target of 2.5 
b. Patients with a bioprosthesis in the mitral position should receive 3 months of anticoagulation with warfarin 
with an INR target of 2.5. 
Patients with a bioprosthetic valve and a history of systemic embolism should have at least 3 months of 
anticoagulation with warfarin with an INR target of 2.5. 
Patients with a bioprosthetic valve and left atrialthrombus at surgery should receive warfarin until the clot 
has resolved with an INR target of 2.5. 
Patients with bioprosthetic valves and other prothrombotic risk factors, such as atrial fibrillation and low 
ventricular ejection fraction, should receive warfarin with an INR target of 2.5. 
c. Patients with intermittent claudication should not routinely be treated with anticoagulants. 
 Patients who suffer acute arterial embolism and proceed to embolectomy should be considered for long-term 











1.2. Atrial fibrillation 
AF is the most common cardiac rhythm abnormality and is associated with significant morbidity, 
especially heart failure and stroke or thrombo-embolism,as well as mortality. A report in 2010 on the 
worldwide epidemiology of atrial fibrillation reported the estimated burden of AF and atrial flutter as 
33.5 million individuals with increasing trends identified since 1990 (Figure 1). In this report, males 
were more affected than females
3
. 
Although the prevalence of AF is less studied in Africa than in the developed world, global data from 
the 2010 epidemiology study reports it is as less prevalent but it is expected to increase significantly 





Figure 1: World map showing the age-adjusted prevalence rates (per 100 000 population) 





There are two well accepted categories of AF namelyAF associated with valvular heart disease and 
non-valvular AF. AF associated with valvular heart disease is commonly associated with a prosthetic 
heart valve, valve repair, or rheumatic valvularheart disease, most commonly stenotic lesions 
involving the mitral valve. Patients with non-valvular AF have no associated underlying causative 
heart disease, and are at high risk for stroke, irrespective if classified as paroxysmal, transient or 
permanent AF
5
.However, findings from the Rivaroxaban Once daily oral direct factor Xainhibition 
compared with vitamin K antagonismfor prevention of stroke and Embolism Trial in Atrial 
Fibrillation (ROCKET-AF) study which randomised 14 264 patients showed that those with 




Forty-five percent of all embolic strokes can be accounted for by AF. In patients in their ninth decade 
of life, it was found that 36% of these patients had sustained strokes due to AF. Overall, AF increases 
the risk of stroke five-fold, and when compared to patients with non-AF–related strokes, are 






.The Framingham study has noted AF as an independent risk factor for stroke
8
. 
The risk of stroke occurrence in AF is reduced by anticoagulant therapy and all major guidelines 
emphasise the role of oral anticoagulation use for stroke prevention
5,7,9
. 
There are many risk factor tools used in clinical practice to assess the risk of stroke in non-valvular 
AF and therefore the need for anticoagulation, however the most accepted is the use of a point scoring 
system called CHA2DS2-Vascscore (Table 2 and 3) which was initially validated in the Euro-Heart 
survey cohorts. In a systemic review comprising 122 articles and 92 different studies, it was found 
that the CHA2DS2-Vasc score had the best risk factor predictor for stroke in AF and the HASBLED 
score (discussed further on) the best predictor of bleeding risk
10
. The CHA2DS2-Vascscoreis now the 
recommendedrisk score by European, US, and National Institute for Health and Care Excellence 
(NICE) guidelines. 
 











Age > 75 years old 2 








Sex -Female 1 
TIA, Transient ischaemic attack 
a-The presence of signs and symptoms of either right or left ventricular failure or both, confirmed by non-
invasive or invasive measurements demonstrating objective evidence of cardiac dysfunction. E.g. LVEF < 40% 
(Left ventricular ejection fraction) 
b- A resting blood pressure >140mmHg systolic and/or >90mmHg diastolic on at least two occasions or current 
antihypertensive pharmacologic treatment c- Fasting plasma glucose level ≥7.0 mmol/L or treatment with an 
oral hypoglycaemic agent and/or insulin d-Prior myocardial infarction, angina pectoris, percutaneous coronary 
intervention or coronary artery 
bypass surgery. The presence of any the following: intermittent claudication, previous surgery or 
percutaneous intervention on the abdominal aorta or the lower extremity vessels, abdominal or thoracic surgery, 
arterial and venous thrombosis 
 
 
There are multiple studies proving benefit with warfarin in AF for stroke prevention over placebo or 
an antiplatelet agent 
11-15
.The five major studies 
11,13,16-18
proving benefit of anticoagulation over 
placebo or aspirin have demonstrated a 69% risk reduction when data was pooled (Table 4). 
 
 


















Table 4: Studies evaluating anticoagulation benefit over placebo or antiplatelet therapy in 
reducing the risk of stroke 
 
Study/Trial Number of cases RRR
a
(%) Target INR range 
AFASAK
b
 1007 (335 on warfarin) 56 2.8 to 4.2 
BAATAF
c
 420 86 1.5 to 2.7 
SPAF
d
 1330 67 2.0 to 3.5 
CAFA
e
 378 37 2.0 to 3.0 
SPINAF
f
 571 79 1.4 to 2.8 
EAFT
g
 1007 (669 on warfarin) 62 2.5 to 4.0 
SPAF III 1004 74 2.0 to 3.0 
    
a- Relative Risk Reduction 
b- AFASAK, Copenhagen Atrial Fibrillation, Aspirin and Anticoagulation Study 
c- BAATAF, Boston Area Anticoagulation Trial for AtrialFibrillation Study 
d- SPAF, stroke prevention in Atrial Fibrillation Study 
e- CAFA, Canadian Atrial Fibrillation Anticoagulation Study 
f- SPINAF,Veterans Affairs stroke prevention in Non-rheumatic Atrial Fibrillation Study 




1.3. Heart valve prosthesis 
 
Since the introduction of valve replacement surgery in the early 1960s, the outcome of patients with 
valvular heart disease has dramatically changed. The most common indications for a prosthetic heart 
valve replacement are due to stenotic or regurgitant lesions in the aortic valve or mitral valve. Aortic 
stenosis (AS) in developed regions is usually the sequel of degenerative change, however, in South 
Africa and other developing countries, the burden of rheumatic fever with recurrent episodes and 
subsequent rheumatic heart disease contributes toward the majority of cases of valvular lesions 
requiring surgical replacement and this remains a concern. 
The American College of Cardiology/American Heart Association (ACC/AHA)recommends aortic 
valve replacement in AS for any symptomatic patient with moderate or severe AS, asymptomatic 
patients with severe AS undergoing coronary artery bypass grafting (CABG) or surgery on the aorta 
or other heart valves or for asymptomatic patients with severe AS with left ventricle systolic 
dysfunction, an abnormal response to exercise, ventricular tachycardia, left ventricle hypertrophy in 
excess of 15 mm or an aortic valve area of less than 0.6cm
2 19
. 
The ACC/AHA recommendations for aortic valve replacement in patients with aortic regurgitation 
(AR) are for any symptomatic patient with severe AR irrespective of left ventricular systolic function, 
in asymptomatic patients with chronic and severe AR with left ventricular systolic dysfunction 
(Ejection fraction less than 50% at rest), in patients with chronic and severe AR or moderate AR 
undergoing CABG or surgery on the aorta or on other heart valves, or in asymptomatic patients with 
severe AR with normal left ventricle (LV) function but severe LV dilatation [End Diastolic Diameter 
(EDD) greater than 75mm or End Systolic Diameter (ESD) more than 55mm] and in asymptomatic 
patients with severe AR and normal LV function at rest with an EDD more than 70mm or ESD more 
than 50mm with declining exercise tolerance 
19
. 
According to ACC/AHA guidelines,mitral valve surgery is indicated in patients with symptomatic 




(MS) if percutaneous mitral balloon valvotomy is contraindicated or unavailable or in symptomatic 
patients with moderate to severe MS who also have moderate to severe mitral regurgitation and in 
patients with severe MS and severe pulmonary hypertension [Pulmonary Artery Stiffness (PAS) 
>60mmHg] who have NYHA functional class I-II symptoms 
19
. 
Patients with prosthetic valves are at risk of thrombo-embolic complications, including systemic 
embolisation, most commonly cerebral and prosthetic thrombosis causing valve obstruction and/or 
regurgitation. The risk of thrombo-embolic events is higher with mechanical than with bioprosthetic 
valves; higher with mitral than with aortic prosthetic valves; and higher in the early (3 months) versus 
late postoperative phase 
20
. The risk is also increased in the presence of concomitant risk factors for 
thrombo-embolism, including AF, LV dysfunction, left atrial dilation, previous thrombo-embolism, 
and a hypercoagulable condition
2
. 
Prosthetic valve thrombosis is a rare but catastrophic complication with a mortality of approximately 
10% 
21
. The reported incidence is 0.3 to 1.3% patient-years. Thrombo-embolism is the more common 
complication reported as 0.7% to 6% patient-years
21
. 
Patients with mechanical prostheses require lifelong anticoagulation with warfarin. In the case of an 
implanted bioprosthesis, anticoagulation with warfarin for 3 months is recommended and some 
authors recommend warfarin use for a period of 6 months following an aortic valve prosthesis 
22
. 
Lifelong anticoagulation is required in the case of a bioprosthesis implantation if the patient has other 




1.4. INR target range 
INR target ranges vary per indication and per country. The most common usual INR target is a range 
from 2 to 3 with the midpoint of 2.5 being targeted as optimal (Table 1). The optimal range is 
determined by defining the risk of thrombo-embolism against the risk of bleeding. 
The accepted target INR range in AF is from 2 to 3 and a midpoint of 2.5 targeted as optimal. Many 
studies have shown reduced incidence of stroke and mortality in patients who are anticoagulated with 
warfarin and subsequent studies have shown reduced efficacy in stroke prevention with INR values 
targeted below thisrange
23
. A record linkage analysis by Odenetal., evaluated the findings from 
medical literature from 1980 to mid-2004 and concluded that INRs in the interval range of 2.0 to 2.5 
give the lowest risk of stroke and death in patients with non-valvular AF 
24
. 
The risk of haemorrhage remains a concern with any patient being anticoagulated with warfarin and 
generally accepted as a two-fold risk to the normal population. Gastrointestinal haemorrhage is much 
more common than intracranial haemorrhage, however intracranial events are usually more 
devastating. In one study evaluating 13 559 patients being anticoagulated for stroke prevention in 
non-valvular AF, 76% of patients who had intracranial haemorrhage had severe disability or died 
compared to 3% of patients with extracranial haemorrhage. Ninety percent of warfarin-associated 
deaths could be accounted for by intracranial haemorrhage
25
. It should be noted, however, that 
warfarin use reduced the 30 day mortality from ischaemic stroke
26
. INR levels greater than 4.00 have 





There are many bleeding risk assessment tools used in clinical practice. One such, commonly used in 
our clinical setting is the HASBLED risk assessment tool (Table 5).This has been validated in 
multiple studies and a systematic review comprising 122 articles and 92 unique studies noted the 




Table 5: HASBLED scoring tool 27 
 
 





Abnormal liver function 1 













a- Uncontrolled or systolic blood pressure greater than 160 mmHg 
b- With the time in therapeutic range less than 60% 
c- Antiplatelet or non-steroidalanti-inflammatory 
d- At least eight units per week 
 
The clinical risk estimation of bleeding is 1.13 per 100 patients with a HASBLED score of zero and 
increases steeply as the score increases. Patients with a score of five have an estimated bleeding risk 
of 12.5 per 100 patients
27
. 
The recommended INR targets for mechanical heart valves depends on the prosthesis thrombogenicity 
[Low: Carbomedics (aortic position), Medtronic Hall, St Jude Medical (without silzone); Medium: 
Bjork-Shiley, other bi-leaflet valves; High: Starr-Edwards, Omniscience, Lillehei-Kaster] as well as 
patient factors which increase the risk of thrombo-embolism (Mitral, tricuspid or pulmonary position; 
previous arterial thrombo-embolism; AF; left atrium diameter more than 50 mm; MS of any degree; 
left ventricular ejection fraction of less than 35%; left atrial dense spontaneous echo contrast). 
Patients with low prosthetic thrombogenicity and no patient risk factors should have an INR target of 
2.5. Those with low prosthesis thrombogenicity and patient risk factors should be optimised at an INR 
of 3.0. Patients with medium prosthesis thrombogenicity and no patient risk factors have an INR 
target of 3.0 whereas those with patient risk factors should have INR levels at 3.5. In patients with 
high prosthesis thrombogenicity, regardless of patient risk factors, an INR of 3.5 should be targeted 








Table 6: Recommended target INR for mechanical valve prosthesis 
2
 
Recommended INR Target 
Thrombogenicity No Risk Factors Risk Factors Present 
Low 2.5 3.0 
Medium 3.0 3.5 
High 3.5 3.5 
 
 
1.5. Assessing the quality of anticoagulation 
The clinical benefits of warfarin as an anticoagulant as well as its haemorrhagic risks are related to the 
proportion of time spent within the target INR range. Anticoagulation with warfarin has a large inter-
individual variability and INR monitoring is serially recommended in order toadjust the treatment 
dose. Patients using warfarin have been well studied for stroke risk reduction and have been used in 
many clinical trials as an indicator for anticoagulation; however the quality of this anticoagulation is 
less often measured. The TTR is an acceptable measure of this and confers the quality of 
anticoagulation control and better defines increased risk of haemorrhage. 
There are at least three different generally well accepted methods to measure TTR, each with its own 
advantages and disadvantages (Table 7): 
1. Fraction of INRs in range (taken as the number of INRs in range divided by the total number of 
INRs for the study interval). This is referred as the Direct method. 
2. The cross-section-of-the-files-methodology (takes each patient whose INR is in range at one point 
in time divided by the total number of INRs done on all patients at that point in time). 
3. The Rosendaal Linear Interpolation Methodology(uses a computer software programthat assumes a 
linear relationship exists between two INR values and allows one to calculate a specific INR value to 


















Methodology Advantages Disadvantages 
Fraction of INRs Simple to calculate More frequent testing in unstable 
patients may bias results  
 Requires only one INR value per 
patient 
Does not take into account actual 
days within target range 
 Not influenced by extent of INR 
outofrange 
Does not consider individual 
patients 




Simple to calculate 
 
Does not take into account actual 
days within range 
 Considers individual patients Only considers one point in time 







Takes into account actual days in 
target range 
 
Calculation is more difficult 
 Allows calculation of INR specific 
incidence rates of adverse events 
Makes assumptions about INR 
between actual tests 
  Does not consider individual 
patients 
  Extreme out of range results may 
bias results 
 
TTR is an important and validated quality measure for VKA management
30
. Patients who are under-
treated remain at risk of thrombo-embolic events and patients who receive too much anticoagulant 
therapy are exposed to unnecessary bleeding risk 
31
. In the setting of non-valvular AF, patients who 
have at least one other stroke risk factor are recommended to receive effective stroke prevention 
therapy, which is essentially an oral anticoagulant (OAC) with well-controlled VKA therapy which 
implies an INR 2 to 3 and a high TTR percentage of at least 60% 
5
. The efficacy of warfarin as an 
anticoagulant is reliant on the time in therapeutic range. Recent studies comparing the novel 
anticoagulant dabigatran showed no difference in stroke prevention at higher TTR
32
. Furthermore, a 




In patients with AF, the quality of anticoagulation is therefore accepted as stratified according to the 
percentage TTR less than 50% conferring bad quality, more than 60% being satisfactory and more 
than 70% conferring optimal anticoagulation. Patients who are under-anticoagulated are at an 
increased risk of thrombo-embolic events. The report from a posthoc analysis of the Atrial fibrillation 
clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W) indicated that if the 






A high variability of the INR is the strongest independent predictor of reduced survival after 
mechanical valve replacement. Valve thrombosis is most often encountered in patients with 
mechanical valves and inadequate antithrombotic therapy
20
.A correlation between treatment quality 
with warfarin as measured by TTR and serious complications has been shown. It is recommended that 
best benefit in patients with prosthetic heart valves is achieved when the TTR is at least 83% but a 
TTR of at least 70% is likely to be sufficient to prevent valve thrombosis
35
. 
Further to the efficacy of anticoagulation, improved TTR confers reduced risk of bleeding and 
mortality. In the SPORTIF III trial (Stroke Prevention using an Oral Direct Thrombin Inhibitor 
inatrial fibrillation) patients with a TTR of less than 60% had significantly higher (p <.01) incidence 
of major haemorrhage (3.85%) and mortality (4.20%) than patients with TTR beyond 75% (1.58% 
and 1.69% respectively) 
36
. 
It is now well accepted and emphasised that the TTR matters and has far reaching implications in both 
assessing the quality of anticoagulation, determining efficient anticoagulation and reducing the 
incidence of mortality and major adverse events. 
 
1.6. Monitoring of INR 
Maintaining TTR can be a challenging task due to the variability of warfarin effects between 
individuals and as a result there is no standardised dose when prescribing warfarin. Moreover, dose 
adjustments are necessary according to INR values. There is evidence to suggest that more frequent 
testing improves TTR, but this may be impractical in the clinic setting. The Home INR Study 
(THINRS) sought to evaluate the impact on TTR after one year following the frequency of INR 
testing on patients being anticoagulated for AF or for prosthetic valves. The results of this study 
showed TTR increased as testing frequency increased for the groups that underwent testing every four 
weeks, twice weekly and weekly. The study involved patients who performed self-testing. 
Furthermore, they found a lower proportion of patients who performed self-monitoring than those 
who attended clinics in the population with poor anticoagulation control. The study concluded that 
more frequent INR testing improved TTR and reduced poor patient outcomes
37
. The finding of more 
frequent testing and improved TTR is consistent in other studies, notably the Self-Testing Analysis 
Based on Long-term Evaluation (STABLE) trial that evaluated patients who performed home 
monitoring and concluded a significantly higher TTR (p <.001) in patients who tested weekly (74%) 
than those who tested every 2 to 4 weeks (68.9%) and the superior TTR in more frequent testers was 
consistent across all indications for anticoagulation 
38
. 
The setting in which patients have their INR values monitored may also impact the TTR. In a meta-
analysis evaluating 11 studies (Three randomised controlled trials and eight cohort studies), patients 
managed at specialised anticoagulation clinics had superior TTR than patients managed with usual 
care, however there was no significant differences with regard to mortality, major haemorrhage or 
thrombo-embolic events 
39
. Evaluation from the Outcomes Registry for Better Informed Treatment of 
Atrial Fibrillation (ORBIT-AF)found that patients treated at anticoagulation clinics had higher median 







1.7. Challenges in maintaining quality anticoagulation 
The INR value of patients taking warfarin has substantial inter-individual variability as a result of the 
drug‟s complex pharmacokinetics and pharmacodynamics. In addition there are multiple drug and 
food interactions that have inducing or inhibitory effects on the drug bioavailability, which translates 
to variability in efficacy and therefore TTR. It is recommended that patients who are starting or 
stopping any of these drugs, have more frequent INR testing, in order to adjust warfarin doses 
accordingly. Certain drugs that have no inhibitory or inducing effects on the elimination of warfarin 
can also influence the INR, most notably the non-steroidal anti-inflammatory drugs like diclofenac, 
aspirin in high doses and ibuprofen. 
Patient compliance with treatment remains an important contributing factor. In one study of patients 
with out of range INRs, non-compliance was most commonly noted on 214 occasions (19.8%), food 
interactionon 143 occasions (13.2%), drugs on 109 occasions (10.0%), alcoholic beverage on 34 




One important factor which is seldom evaluated in community-based practice is warfarin resistance 
which should be considered when a weekly dose of at least 105mg does not increase the INR to 
therapeutic range. Warfarin resistance can be acquired(most commonly due to non-compliance with 
treatment) or hereditary (genetic factors that increase metabolism or reduced sensitivity). Studies in 
rats and humans have demonstrated abnormalities with increased affinity of vitamin K 1, 2, 3-epoxide 
reductase (VKOR) for vitamin K and decreased VKOR sensitivity to warfarin. 
 
1.8. Alternative therapies to warfarin for anticoagulation 
Recently, the introduction of non-warfarin, new oral anticoagulant (NOAC) agents have resulted in 
exciting studies comparing efficacy for stroke prevention and bleeding complications against warfarin 
in AF. Three novel drugs (and their respective studies), dabigatran (Re-ly), apixaban(ARISTOTLE) 
and rivaroxaban(ROCKET-AF) have been studied for efficacy and safety against warfarin and have at 




NOACs are as yet not approved for anticoagulation in patients with prosthetic heart valves and 





1.9. The research objective 
It is well accepted that patients with non-valvular AF and patients with prosthetic heart valves require 
anticoagulation to prevent thrombo-embolic complications. There are many studies proving this 
benefit
11,13,16-18
. More recently, with the introduction of the NOACs, warfarin has been challenged as 
the gold standard drug for AF in non-valvular AF. The studies surrounding this evaluation show the 
efficacy in stroke prevention in AF is comparable to warfarin. The TTR, however, is less often 
evaluated for patients taking warfarin. Many studies evaluated TTR in a clinical trial setting
30,42,44
. 
Other studies evaluated the influential factors surrounding these patients 
31
, however most studies 
analyse patients in a controlled trial or in an anticoagulation clinic 
39
 or those using self-testing or self-
monitoring techniques 
37,38
 that may over-estimate the TTR. In our study, we attempted to evaluate the 
quality of anticoagulation in a patient population who are not part of a comparative trial, who do not 
utilise self-monitoring or self-testing devices, who attend a community-based district level hospital 
and not in the way of a specialised anticoagulation clinic and who do not have access to the NOAC 
agents. 
Our specific objectives: 
1. Assessedthe overall quality of anticoagulation in patients using warfarin as an oral 
anticoagulant for prevention of stroke in patients with non-valvular AF and in patients with 
prosthetic heart valves by determining the TTR. 
2. Compared two different methods used to evaluate TTR namelythe Direct method (Fraction of 
INRs in range) and the Rosendaal method (Linear Interpolation of INRs). 
3. Determined the overall time out of range i.e.the mean percentage of time being under-
coagulated, the percentage of time being over-anticoagulated and the percentage time with an 
INR value in excess of 4.00 which is associated with a high risk of haemorrhagic 
complications. 
4. Evaluated the indications for anticoagulation with warfarin in this patient population. 
5. Evaluated factors that may be associated with TTR or out of range, specifically, gender, age 
and frequency of monitoring and in the case of patients with prosthetic valves, for different 
target INR ranges. 
6. Evaluated the point prevalence of adverse events, specifically, stroke, haemorrhage, any 
admission for warfarin toxicity and any cases of prosthetic valve thrombosis in this patient 
population and determined if there was an association between events and the factors listed 
above. 
7. Evaluated for significant difference between patients who sustained a stroke and those who 






METHOD AND STUDY DESIGN 
 
This is a retrospective, descriptive and observational study with chart audits. Review of the literature 
was done by an online search in Pub Med with the following keywords; atrial fibrillation, time in 
therapeutic range, warfarin, mechanical valve prosthesis, thrombo-embolic stroke, haemorrhage and 
the abbreviations or acronyms; INR, TTR, CHADvasc, HASBLED and AF. 
Patients attending the adult medical outpatient department at Mahatma Gandhi Memorial Hospital in 
KwaZulu Natal, South Africa comprised our patient population. All patients who had INR 
measurements over a period of four months were initially selected. INR testing in this centre is 
performed by sampling venous blood in a citrate tube. We determined this with the assistance of the 
National Health Laboratory Service (NHLS) based at the hospital by providing the phlebotomy log 
books for this period. We then removed all duplicate cases as well as patients who were not using 
warfarin to determine the preliminary sample size. Systematic random sampling was utilised and the 
random number selected was one and therefore we evaluated every case. Patients were then allocated 
a case number („n‟) by true randomness and this was selected by an online internet tool from 
“Random.org” that uses atmospheric noise rather than algorithmic methods to randomise samples. 
We then conducted a comprehensive retrospective chart review for each patient. We thereby 
determined the indications for anticoagulation in the population. Data collected from chart reviews for 
each patient included the following: 
1. The indication for anticoagulation. Thereafter, all patients treated with warfarin for reasons 
other than stroke prevention in non-valvular AF orfor prosthetic heart valves were excluded 
from further study which is how the final study population was determined. 
2. The age of each patient in completed years. 
3. Gender. 
4. Date of INR sampling (which was used to determine the days between tests and total days 
studied for each patient) with the corresponding INR value. 
5. Target INR range as per the indication (2.0 to 3.0 for AF and variable for valve prosthesis). 
6. The presence or absence of patient risk factors and valve thrombogenicity in cases with 
prosthetic valves in order to determine the target INR range. 
7. The percentage of time below range, above range, with INR values greater than 4.00 and in 
range using the Direct method (The ratio of INR values in range out of the total number 
sampled as a percentage). 
8. Any adverse event and type of event that was sustained during any period while being 
anticoagulated and not limited to the data collection period. 
9. The data collection tool (Appendix 5) was allocated a case number „n‟ to ensure patient 
anonymity. 
10. The TTR using the Rosendaal method.We transcribed this data into the MicrosoftR Excel 
program. 
11. All INR values and dates of tests were recorded for at least one year or 12 consecutive INR 
values, whichever was the longer for each individual patient. 






The research period was from November 2015 (Approval date of ethics and gatekeeper permission) to 
September 2016 (Collection and analysis of data and completion of draft write-up). 
The inclusion criterion for participants for both non-valvular AF and valve prosthesis was: 
1. Outpatient cases were considered. 
2. Patients who were older than 12 years old were evaluated. 
3. Patients who were taking warfarin for at least one year were considered. 
4. Patients who had mechanical heart valves were considered. 
The following exclusion criteria applied to the study: 
1. Inpatients and any INR value while an inpatient was not included. 
2. Patients who were less than 12 years old were not considered. 
3. Patients who were taking warfarin for less than one year were excluded. 
4. Patients who had interrupted warfarin use for longer than two months was excluded e.g. 
pregnant patients. 
5. Patientswho were being anticoagulated with warfarin for reasons other than non-valvular AF 
or prosthetic heart valves were not included for further study beyond contributing to the data 
evaluating the indications for anticoagulation in the study location. 
We evaluated the time in therapeutic range by two methods: 
1. The Direct method was determined by evaluating the number of INR values in range out of 
all INR tests for that patient as a percentage. Similarly, the time below range, time above 
range and time with INR levels greater than 4.00 were determined in this way. 
2. The Rosendaal method of determining the time in therapeutic range was determined by 
analysis with the Microsoft
R
 Excel programme. 
Time out of range (Time below range, above range and with an INR value greater than 4.00) was 
determined using only the Direct method. 
Data was analysed bythe IBM Statistical Package for the Social Sciences (SPSS)for Windows
R
, 
version 23 (IBM Corp., Armonk, N.Y., USA) software program. Descriptive statistics included mean 
(M) and standard deviation (SD) for quantitative data and frequencies for categorical data. Variables 
with means which demonstrated uniformity with linear Q-Q plots and/or P-P plots were conducted by 
parametric testing using the independent samples T-test and Hartley‟s statistical test for variance for 
normally distributed data. Pearson‟s chi-square test was used for categorical data. Analysis of 
variance (ANOVA) was conducted for comparisons of variables with post hoc analysis by Tukey 
honestly significant difference (HSD) for analysis of three or more groups. Homogeneity of variance 
statistical testing was conducted using Levene‟s test for quality of variance. Confidence intervals were 
reported as 95%. Two-tailed p-values were conducted and any p-value less than.05 was considered 
significant. 
Topic Specific methods 
In evaluating TTR, we used the Pearson correlation test to evaluate the Direct and the Rosendaal 
methods. After determining and analysing the overall TTR for both cohorts, we then categorised 
patients in the AF cohort into the percentage of patients with TTR less than 60% which was 
considered as suboptimal anticoagulation and time with increased thrombotic risk, percentage of 




percentage of patients with TTR more than 70% which was considered as excellent anticoagulation 
quality. Patients with TTR more than 60% but less than 70% were considered as having satisfactory 
anticoagulation. Thereafter, we compared the groups with TTR more than 70% with the TTR less than 
60% group according to the results of the Rosendaal method for the conditions of gender, age, 
average days between tests and the presence of at least one documented adverse event. 
We then analysed all patients in the valve prosthesis cohort with regard to TTR and stratified the 
cohort according to percentage of patients with TTR of at least 70% which was considered 
satisfactory, the percentage of patients with TTR of at least 83% which was considered as ideal and 
the percentage of patients with TTR less than 70% which was considered suboptimal. 
The frequency of INR testing was categorised into three groups namely; less than 28 days apart; 28 to 
32 days apart and more than 32 days apart. 
The target INR value for patients with prosthetic heart valves was determined by using the 
recommendations by Keeling et al.,Guidelines on oral anticoagulation with warfarin - fourth edition. 
Br J Haematology, 2011. 154(3): p. 311-24 (Table 6). This was opted for in view of the laboratory 
service at this clinical setting adopting the same recommended guideline in their reference for target 
INR ranges and therefore maintained a consistency between the treating clinician and evaluation in 
this study.In order to create a target INR range, we accepted the above targets as the minimum 
acceptable INR value and allowed a 0.5 higher limit to create a range. The target INR range for 
patients with AF was consistent at 2.0 to 3.0. 
We studied all patient population outpatient files to determine the prevalence of any documented 
adverse event. The study duration in terms of evaluating INR values for each patient spanned only one 
year, and we therefore sampled any documented adverse event at any time for a particular patient 
while on anticoagulation. Any event that occurred prior to the patient commencing long-term 
anticoagulation was not considered. Data capture for any adverse event was reliant on the clinicians‟ 
documentation of such as well as any attached discharge note following an inpatient care or any 
referral note attached to the outpatient file. 
Adverse events were categorised as any stroke, which was not defined as ischaemic or haemorrhagic 
(primarily due to lack of easy access to neuro-imaging at the study location and therefore most 
patients with a stroke had no documented computed tomography of the brain or magnetic resonance 
imaging reports) and any event with haemorrhage or warfarin toxicity (Defined as warranting antidote 
treatment and/or inpatient care). Any episode of minor haemorrhage not requiring admission was 
discounted. In addition, we assessed for cases of a thrombosed or obstructed prosthetic valve in the 
context of the patients requiring anticoagulation for prosthetic heart valves. 
We determined the point prevalence of these adverse events for the sample population as a whole and 
then separately for the AF cohortand the valve prosthesis cohort. Analyses include evaluating for 
associations of adverse events with time in range, time out of range, age, gender, INR testing interval 
and target INR range (valve prosthesis sub-cohort) using a Poisson regression using Wald chi-square 







DESCRIPTION OF THE SAMPLE POPULATION 
 
We determined the indication for anticoagulation in a single centre, community-based district level 
hospital in Phoenix, Durban, KwaZulu Natal, South Africa by performing a comprehensive chart 
audit on all patients who had INR measurements at the hospital during a four-month period. We 
observed 678 different INR tests performed over this period (Figure 2). Thereafter, we removed 
duplicate patients and patients who had INR testing who were not taking warfarin. The remaining 263 
individual cases were evaluated according to the indication of anticoagulation at this centre (Table 8). 
All individual data was collected and collated by review of the patients‟ hospital outpatient chart. 
 
Table 8: Indications for anticoagulation 
Indication n (%) 
  
Non-valvular AF 104 (39.5) 
Prosthetic heart valves 94 (35.8) 
VTE / DVT / PE 32 (12.2) 
Arterial / LV Thrombus 13 (4.9) 
Valvular AF 10 (3.8) 
CMO with Low EF 1 (0.4) 
Files not located/Undetermined 9 (3.4) 
  
Total 263 (100%) 
AF- Atrial fibrillation, VTE-Venous thrombo-embolism, DVT- Deep vein thrombosis, PE- pulmonary embolus, 
LV-Left ventricle, CMO-Cardiomyopathy, EF-Ejection fraction 
 
Patients who were anticoagulated for indications other than for non-valvular AF or for prosthetic heart 
valveswere thereafter excluded from further study (Table 8). A further eight patients from the non-
valvular AF subset and 13 patients from the valve prosthesis subset had been anticoagulated with 

























Figure 2: Schematic showing how the sample population was determined. 
 
In order to evaluate the quality of anticoagulation we sampled a total of 177patients using warfarin for 
non-valvular AF (n=96) and for prosthetic heart valves (n=81) attending the outpatient department at 
Mahatma Gandhi Memorial Hospital. The sample population was not part of a specialised 
anticoagulation clinic. 
Descriptive statistics for this sample population included data analyses for gender, age in years and 
categorised for each subpopulation, total number of days studied per individual patient, the number of 
INR tests performed per individual patient and the interval days between each test. SDwas used to 
describe the dispersion (Table 9). 
The majority of the patients in our sample population were female (68.9% for the entire sample 
population (n=122), 65.6% (n=63) for AF cohort and 72.8% (n=59) for valve prosthesis cohort). 
The mean age of the entire cohort was 54.23 years (SD=17.6), 64.68 years (SD=11.27) for the AF 
cohort and 41.83years (SD=15.67) for the valve prosthesis cohort. 
We categorised the age of patients in the AF cohort in line with the CHA2DS2-Vascscoring system. 
Patients who were at least 65 years old to less than 75 years old accounted for 35.4% (n=34) of the AF 
cohort and patients 75 years or older accounted for 17.7% (n=17). The remaining 46.9% (n=45) of 
patients in the AF cohort were younger than 65 years old. 
 
678 Cases who had INRs sampled in Outpatient Department over a 4 month period 
 
263 Cases after removing duplicate cases and cases not on warfarin 
 







96 Cases – Anticoagulation with Warfarin for stroke prevention with Non-
Valvular AF 




Patients in the valve prosthesis cohort were categorised into six age categories with the fewest patients 
(2.5%, n=2) younger than 20 years. The majority of the patients (48.1%, n=39) were from 20 years 
and less than 40 years old with 17.3 % (n=14) aged at least 60 years old. The remaining 32.1% (n=26) 
of patients in the valve prosthesis cohort were from 40 years and less than 60 years old. 
The total number of days evaluated for the entire cohort was 78975 days or 216.4 years with a mean 
of 446.2 days (SD=157.1) per patient. The AF cohort was evaluated for a period of 39937 or 109.4 
years with a mean of 416 days(SD=111.8) per patient and the valve prosthesis cohort was evaluated 
for 39038 days or 106.9 years with a mean of 481.9 days (SD=192.4) per patient. 
The mean number of days between INR tests for the entire cohort was 33.3 days (SD=12.03); 31.05 
days (SD=6.77) for the AF cohort and 35 days (SD=15.82) for the valve prosthesis cohort. 
A total of 2382 INR values were analysed for the entire cohort (N=177) with 1285 INR tests studied 
for the AF cohort and 1097 INR tests studied for the valve prosthesis cohort. 






















Table 9: Characteristics of the sample population. 
Sample Population (N=177)   
Female, n (%)  122 (68.9) 
Male, n (%)  55 (31.1) 
Mean age (SD)  54.23 (17.6) 
Median age (Min, Max)  57 (15,91) 
Inter-quartile age range  40-69 
Total Days studied (Mean per patient)  78975 (446.2) 
Total INRs sampled (Mean per patient)  2382 (13.5) 
Mean days between INR tests (SD)  33.3 (12.0) 
Less than 28 days apart, n (%)  41(23.2) 
28 to 32 days apart, n (%)  75(42.3) 
More than 32 days apart, n (%)  61(34.5) 
   
AF Cohort (n=96)   
Female, n (%)  63 (65.6) 
Male, n (%)  33 (34.4) 
Mean age (SD)  64.7 (11.3) 
Median age (Min, Max)  66 (36, 91) 
Inter-quartile age range  57-72 
Less than 65 years old, n (%)  45(46.9) 
65 to less than 75 years old, n (%)  34 (35.4) 
75 years or older, n (%)  17(17.7) 
Total days studied (Mean per patient)  39937 (416) 
Total INRs sampled (Mean per patient)  1285 (13.4) 
Mean days between INR tests (SD)  31.1 (6.8) 
Less than 28 days apart, n (%)  31(32.3) 
28 to 32 days apart, n (%)  36(37.5) 
More than 32 days apart, n (%)  29(30.2) 
   
Valve Prosthesis Cohort (n=81)   
Female, n (%)  59 (72.8) 
Male, n (%)  22 (27.2) 
Mean age (SD)  41.8 (15.7) 
Median age (Min,Max)  39 (15, 76) 
Inter-quartile age range  30-55 
 Less than 20 years old, n (%)  2 (2.5) 
20 to 29 years old, n (%)  18 (22.2) 
30 to 39 years old, n (%)  21 (25.9) 
40 to 49 years old, n (%)  14 (17.3) 
50 to 59 years old, n (%)  12 (14.8) 
60 years or older, n (%)  14 (17.3) 
Total Days studied (Mean per patient)   39038 (482) 
Total INRs sampled (Mean per patient)  1097 (13.5) 
Mean days between tests (SD)  36 (15.8) 
Less than 28 days apart, n (%)  10 (12.3) 
28 to 32 days apart, n (%)  39 (48.2) 







TIME IN THERAPEUTIC RANGE 
 
4.1. Introduction 
Although anticoagulation with warfarin and its‟ target range for AF and prosthetic valves is well 
accepted, the quality of this anticoagulation is less often evaluated. The time in therapeutic range is a 
well validated tool for assessing anticoagulation quality. There are three accepted measures of 
determining the TTR which has been discussed previously in this work. Each has advantages and 
disadvantages over the other. The most used methodsamong the major published workis the 
Rosendaal interpolation method and the Direct method. 
AF, prosthetic valves and the complex pharmacodynamics of warfarin itself preclude to a narrow 
therapeutic window to prevent thrombosis and to minimise the risk of haemorrhage. The TTR has 
been evaluated as being an important measure of this balance. The ACTIVE-W trial found the benefit 
of stroke prevention with warfarin over aspirin and clopidogrel was lost if the TTR was less than 
58%
34
. The study by Wan et al., evaluated anticoagulation control and prediction of adverse events in 
patients with AF by a systematic review of 47 studies. They found that TTR negatively correlated 
with major haemorrhage (r= -0.59; p-0.002) and thrombo-embolic rates (r= -0.59; p-0.01). This effect 
was significant in retrospective studies but not in randomised controlled trials. For retrospective 
studies, a 6.9% improvement in the TTR significantly reduced major haemorrhage by one event per 
100 patient-years of treatment. Furthermore, they concluded that a 12% increase in TTR can reduce 
the thrombo-embolic rate by one event per 100 patient years
45
. Data from the ROCKET-AF trial, 
evaluated the relationship between TTR and the comparative treatment effects of rivaroxaban and 
warfarin and found that patients in the highest quartile of TTR had a lower event rate per 100 person-
years than patients in the lowest quartile of TTR (1.3 vs 2.0) when analysing stroke or systemic 
thrombo-embolism
46
.In a study by Gallagher et al., which evaluated the risk of stroke and mortality 
with suboptimal anticoagulation in patients with AF found that patients who spent at least 70% of 
time within therapeutic range had a 79% reduced risk of stroke compared to patients with ≤30% of 
time in range (adjusted relative rate of 0.21; 95% confidence interval 0.18–0.25). They also reported 
significantly lower mortality rates with at least 70% of time spent within therapeutic range
47
. 
There is considerable variabilty in TTR within centres and across centres. Analysis of the data from 
the ARISTOTLE trial by Wallentin et al., which randomised 18201 patients from 1034 centres and 39 
countries reported substantial variation in INR control, with median TTR ranging from 49% to 78%. 
The variability in the time below therapeutic range ranged from 9% to 47%. Time above the 
therapeutic range (INR greater than 3.0) was more constant with a range from 5% to 15% across 
countries
44
. A regional variation in TTR was also demonstrated in the RE-LY study
42
. 
There are various factors that affect the TTR and therefore the quality of anticoagulation. 
Apostolakiset al., analysed data from the Atrial Fibrillation Follow-up Investigation of Rhythm 
Management (AFFIRM) trial and evaluated the following factors as having significant impact on 
TTR; female sex (p<.0001), age less than 50 years (p<.0001), age 50 to 60 years ( p=.02), ethnic 
minority status ( p<.0001), smoking ( p=.03), more than two co-morbidities ( p<.0001), and being 
treated with a beta-blocker ( p=.02), verapamil ( p=.02), or, inversely, with amiodarone 
(p=.05)
31




younger patients having poorer control and a higher frequency of testing. They also demonstrated an 
association with income, with patients living in higher median income regions having higher TTR
48
. 
Another factor that is associated with improved TTR is frequent INR monitoring
38
. 
The TTR should be at least 60% in patients with AF tosatisfy adequate anticoagulation. A TTR of less 
than 50% is considered bad anticoagulation and TTR of 70% or more is excellent. 
A correlation between treatment quality with warfarin as measured by TTR and serious complications 
has been shown. It is recommended that best benefit in patients with prosthetic heart valves is when 
the TTR is at least 83% but a TTR of at least 70% is likely sufficient to prevent valve thrombosis
35
. 
Many reports evaluating the TTR have been as a result of clinical trials or in specialised 
anticoagulation clinics. We sought to determine an unbiased and real-world evaluation of TTR in a 





Analysis of the mean TTR using the Direct method showed that patients in the AF cohort (M=41.9; 
SD=19.6) had a significantly higher percentage of TTR than those in the valve prosthesis cohort 
(M=13.8; SD=12.7), t (164) = 11.4, p- <.001 (Figure 3). 
The TTR measured by the Rosendaal interpolation method also showed significantly higher TTR by 
patients in the AF cohort(M=44.5; SD=18.5) as compared to patients in the valve prosthesis cohort 
(M=13.7; SD=11.9), t (164) = 13.3, p- <.001 (Figure 3). 
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There was no difference in the comparisons of the means between the results from the Direct method 
and the Rosendaal method for the AF cohort (t (190) = -.948, p-.344) or for the valve prosthesis 
cohort (t (160) =.058, p-.953). A Pearson correlation was run between the Direct and Rosendaal 
methods of determining the TTR. There was a strong and highly significant positive correlation 
between the results of the two methods (r=.823, n=96, p<.001). 
We evaluated 1285 INR samples of patients with AF. The mean INR value was 2.70 (SD=1.369). 
Five hundred and forty-six (42.5%) INR values were within the therapeutic range, 367 (28.6%) INR 
values were below the therapeutic range and 372 (28.9%) INR values were above the therapeutic 
range (Figure 4). 
 
 
Figure 4: Histogram depicting INR values in patients with AF 
 
We divided patients from both cohorts into subsets according to the percentage of time in the 
therapeutic range. Of the 96 patients in the AF cohort, ten patients (10.4%) had INR values in the 
therapeutic range for more than 70% of the time and considered to have good anticoagulation, 73 
(76.1%) patients were in therapeutic range for less than 60% of the time and were therefore, sub-
optimally anticoagulated and at increased risk for thrombotic events. Sixty-two patients of the 73 
patients who demonstrated suboptimal TTR (84.9% of this subset or 64.6% of the cohort) 
























































































Figure 5: Distribution of patients in the AF cohort (n=96) according to percentage TTR 
more than 70%, below 60%, below 50% and between 60% and 70% 
 
We then evaluated for differences in characteristics between the different subgroups (Table 10). The 
age in years of the patients between the group with TTR more than 70% (M=62.6; SD=12.6) was not 
statistically significant from the group with TTR less than 60% (M=64.5; SD=10.9) [t (11) = -.463, p-
.652] nor the group with TTR less than 50% (M=66.3; SD=10.0 [t (10.9) = -.882, p-.397]. 
Four (40%) of the ten patients with a TTR more than 70% were male. Associations in gender between 
the groups of patients with TTR more than 70% and those with TTR less than 60% and then less than 
50% were also not significant (p- 1.00 and p-.429 respectively). 
The mean days between tests for the group of patients with TTR more than 70% (M=33.1 days; 
SD=8.7) was not statistically significant when compared to the group of patients with TTR less than 
60% (M=31.1 days; SD=6.8) [t (10.7) =.704, p -.496] nor for the group of patients with TTR less than 
50% [t (10.7) =.829, p-.425]. 
Patients considered to have excellent anticoagulation had nine documented adverse events, seven of 
which, for a documented stroke (undefined) and two for haemorrhage or toxicity requiring admission 
which results in a 90% point prevalence as compared to the group of patients with TTR less than 60% 
who had 15 documented adverse events, eight of which were a documented stroke (undefined) and 
seven for documented haemorrhage or toxicity, which results in a point prevalence of 20.5 %. There is 
however no statistical significance between the group of patients with TTR >70% and those with TTR 
<60% for the condition of at least one documented event [Pearson‟s chi-square test, p-.490]. 
However, the results of Pearson chi-square test, when evaluating the prevalence of adverse events was 





Table 10: Characteristics of patients with AF (n=96) stratified as TTR by the 
Rosendaalmethod 

















Mean age (SD) 62.6 67.1 64.5 66.3 
Age < 65 n (%) 4 (40) 5 (38.4) 36 (49.3) 26 (41.9) 
Age 65 -<75 n (%) 5 (50) 4 (30.8) 25 (34.2) 24 (38.7) 
Age >75 n (%) 1 (10) 4 (30.8) 12 (16.5) 12 (19.4) 
Mean days between tests 33.1 29.1 31.1 30.7 
Total adverse events (n=28) 9 (32.1%)* 4 (14.3%) 15 (53.6%) 15 (53.6) 
 Stroke (18 in total) 7 (38.9%) 3 (16.7%) 8 (44.4%) 8 (44.4) 
 Haemorrhage (10 in total) 2 (20.0%) 1 (10%) 7 (70%) 7 (70) 
Time out of range 
 Mean time below range 
 Mean time above range 

















     
*p -.038 using Pearson chi-square test when compared to < 50% TTR subgroup 
 
The mean TTR in 81 patients with prosthetic heart valves was less than 14 %. None of the patients 
with prosthetic heart valves in our study demonstrated satisfactory quality of anticoagulation and all 
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Figure 6: Percentage of TTR-Valve prosthesis cohort distributed in percentage time >83%, 





Our study demonstrated significant variation in TTR between the two different indications for 
anticoagulation. Patients with AF had a significantly higher TTR than those with mechanical 
prosthetic valves (p<.001). AuriculA, a Swedish study, was one of a few studies that evaluated TTR 
across different indications. Patients with AF in that study demonstrated a mean TTR of 76.5% and 
those with mechanical valves showed a TTR of 79.9%. These findings are in contrast to the findings 
in our study although some study design differences exist; the participants from AuriculA were not 
exclusively managed out of specialised anticoagulation clinics and that study utilised only an INR 
range of 2 to 3
49
. 
We found no statistical difference between the Direct method (fraction of INRs in range) and the 
Rosendaal method. Caldeiraet al., in a study of 377 patients that attended an anticoagulation clinic, 
compared the Rosendaal method to the tests ratio. Similar to the findings in our study, the Rosendaal 
method and the tests ratio correlated well (Rho Spearman 0.88, p<.001), but the Bland-Altman plot 
evaluation showed a clinically relevant data dispersion [95% confidence interval (95% CI) -12.9 to 
23.1] around a mean difference in TTR -5.1% using the tests ratio method. The tests ratio less than 
60% had a sensitivity of 91.6%, specificity of 72.3%, positive predictive value of 72.2% and negative 
predictive value of 91.6%, for the diagnosis of patients inadequately anticoagulated (Rosendaal TTR 
<60%). Tests ratio underestimated TTR in 5% and was not considered equivalent to Rosendaal TTR 
due to the high variability between methods, however they concluded it may be a reasonable option to 
detect inadequate anticoagulation 
50
. In the meta-analysis by Wan et al., it was concluded that the 
fraction of INRs in range was a good proxy to the Rosendaal method and the two methods correlated 
well
45
. Schmitt performed a comparative evaluation of measures of TTR and demonstrated the 
fraction of INRs and the cross-section-of-files methods were similar although the linear interpolation 




The mean TTR in our study was 44.5% and this varied substantially from the findings in other studies. 
Most other studies, albeit, under different conditions have demonstrated far superior mean TTR 
(Figure 7). Various studies have identified a regional variation in TTR
44,46,48
. In a South African study 
conducted in Cape Town which included analysis of participants from an anticoagulation clinic, the 
mean TTR was 48.5%. In the major studies that included South African participants, the mean TTR 
was comparable to findings of our study
34,38,39,44,46-49,51
. Overall, the TTR is poorer in African countries 
compared to the European and western regions. The difference is likely contributed by the burden of 



















































Percentage (%) Mean TTR
Figure 7: Comparisons of TTR from different studies. 
 
The mean age between the subgroups of excellent, satisfactory, poor and bad anticoagulation were not 
statistically significant. Interestingly, however, the subgroup of patients with the highest TTR had the 
lowest mean age. This is inconsistent with the findings from Apostolakiset al., and Dlottet al.,
31,48
. 
Several studies have shown an association with improved TTR and more frequent testing
37,38
, 
however, in our study, although not statistically significant, patients with the best TTR had the least 
frequent testing interval. In a community-based evaluation of TTR by Rose et al., it was demonstrated 
that longer intervals had significantly better TTR and less INR variability (p<.001)
9
. The most 
plausible reason for this finding in our retrospective study is likely due to better controlled patients 
being evaluated less intensely than the poorer controlled patients.In line with findings of the 
SPORTIF III trial
36
, patients in the poorest tier of anticoagulation quality as measured by TTR 
sustained the highest percentage of adverse events for both stroke and haemorrhage. 
Overall, patients in our study population have demonstrated modest anticoagulation control compared 
to studies conducted in Europe and the United States of America. Nonetheless, our findings are 
comparable to other South African and African studies, at least with regard to patients with AF. 
The patients with prosthetic heart valves demonstrated remarkably poor results. All patients from this 
subgroup were categorised as suboptimal anticoagulation and therefore predisposed to both 
thrombotic and haemorrhagic events. Patients in this category were on average younger, have higher 
target INR values and had a higher female representation, all of which are validated factors associated 






COMPARISONS OF TTR AND TIME OUT OF RANGE BETWEEN PATIENTS 
WITH ATRIAL FIBRILLATION AND PROSTHETIC HEART VALVES 
 
5.1. Introduction 
There are various indications for anticoagulation (Table 1). Two notable conditions that stress the 
relevance of quality of anticoagulation as measured by the TTR are in AF and in the presence of 
prosthetic mechanical heart valves. Both these conditions require long-term anticoagulation and the 
TTR is vital to achieving adequate anticoagulation as well as imposing the lowest risk of 
complications. AF is the more studied disease entity with regard to anticoagulation, more so since the 
introduction of non-VKA drugs. However, the majority of patients with AF are still treated with 
VKAs. Presently warfarin is the only drug recommended for the management of patients with 
prosthetic heart valves. 
Apostolakisetal.,noted that influential factors on TTR included female sex, younger age (less than 60 
years old), medical history, interacting drugs, tobacco use and race
31
.The target INR range has also 
been demonstrated as a factor in contributing to anticoagulation quality 
9
. The differing patient 
characteristics with regard to these established factors between patients with AF and mechanical heart 
valve prosthesesimplies a varying degree of quality of anticoagulation.Fewer studies have evaluated 
the quality of anticoagulation as a comparison between the two conditions. 
Our patient population included patients with both conditions and we evaluated for differences in 
anticoagulation quality between the two indications. 
 
5.2. Results 
The mean percentage time in the AF cohort differed significantly from the mean percentage time in 
the valve prosthesis cohort for all conditions (Table 11). Patients in the AF cohort (M=29.19, 
SD=19.89) spent significantly less time below range than the patients in the valve prosthesis cohort 
(M=67.69, SD=20.02). [t (175) = -12.785, p <.001] and significantly more time above range 
(M=28.38, SD=17.21) than the patients in the valve prosthesis cohort (M=18.61, SD=13.88). [t 
(174.661) = 4.177, p<.001]. 
The mean percentage time with an INR value of greater than 4.0 was significantly lower in the AF 
cohort (M=9.11, SD=11.04) than the valve prosthesis cohort (M=13.34, SD=10.91). [t (175) = -2.548 
p-.012] 
The mean percentage TTR using both the Direct method and Rosendaal method was significantly 
higher in the AF cohort (M=41.88, SD=19.64 and M=44.49, SD=18.51) than the valve prosthesis 
cohort (M=13.81, SD=12.76 and M=13.70, SD=11.95). [t (164.8) = 11.431, p <.001 and t (164.3) = 




Table 11: Distribution of mean percentage time in range and out of range for the 
subgroups of AF (n=96) and valve prosthesis (n=81). 
 




Mean Age in years 64.7 41.8 
 
Female sex, n (%) 63 (65.6) 59 (72.8) 
Time Below range (%) 
 
29.2† 67.7 
Time Above range (%) 
 
28.4† 18.6 
Time INR >4.00 (%) 
 
9.1* 13.3 
TTR- Direct method (%) 
 
41.9† 13.8 
TTR-Rosendaal method (%) 44.5† 13.7 
† p<.001 when compared to valve prosthesis subgroup using independent samples t-test. 




Our primary objective was to evaluate the quality of anticoagulation by assessing the TTR. Overall, 
the sample population in our study showed remarkably suboptimal TTR with patients as a whole 
spending only approximately 30% of the time in therapeutic range. The significantly poorer TTR in 
patients with a valve prosthesis compared to those with AF may be attributed to higher target INR 
ranges in these patients and therefore more challenging to the clinician to maintain patients in range. 
In keeping with the findings from Apostolakis etal., the mean age of patients with valve prosthesis 
was more than 20 years less than that of patients with AF and the mean age was less than 50 years old 
which conferred a stronger association (p <.001) with poor TTR than patients aged 50-60 years (p -
.02) 
31
. Furthermore, the valve prosthesis cohort had a larger percentage of females than the AF 
subgroup, which is also a significant factor associated with poorer TTR. 
The most time spent out of range by patients in both cohorts and therefore in the overall sample 
population was below range. Patients with valve prosthesis spent a significant percentage of time 
below range than patients with AF; however patients with AF spent more time above range than those 
with prosthetic heart valves. The most likely influential factor is the target INR range, where patients 
with valve prosthesis have higher targeted INR ranges and therefore are more likely to fall short of 
range than those with AF. Furthermore, there is likely an element of caution applied by clinicians 
when prescribing warfarin for patients with high target INR ranges so as not to increase the risk of 
bleeding. The higher target INR ranges in patients with valve prosthesis are likely why these patients 
in our study spent significantly more time with INR values in excess of 4.00 and are therefore at 
higher risk of haemorrhagic complications. 
The disparity in TTR between the two indications for anticoagulation demonstrated in our study is 
inconsistent with findings from the study conducted in Sweden by Wielochetal.,
49




values from 18 391 patients in 67 different centres and data was evaluated from AuriculA (A Swedish 
national quality registry of patients with atrial fibrillation). In their study, anticoagulation measured as 
TTR was measured across all indications. AF represented the majority of the patients (64%) and heart 
valve dysfunction accounted for 13%. The overall mean percentage TTR for the whole population 
was 76.2% with AF subgroup achieving 76.5% mean TTR and the valve disease cohort specifically 
the subgroup with mechanical valves demonstrated a mean TTR of 79.9%. These findings are 
remarkably different from that of our study. However, there are some noteworthy differences between 
the two studies. In AuriculA, patients in the AF subgroup may have included patients with valvular 
AF. AuriculA only included patients with a low target INR of 2.0 to 3.0 and did not include patients 
managed exclusively out of specialised anticoagulation setting. In addition, the difference in the mean 
age between the AF subgroup and the mechanical valve subgroup was less than 10 years (73 years 
and 65 years respectively) and their study had less female representation. Regardless, these findings 






FACTORS ASSOCIATED WITH TIME IN RANGE AND TIME OUT OF RANGE 
 
6.1. Gender association with time in range and time out of range 
According to the global burden of AF study
3
, the estimated incidence rates of AF in 2010 were 
higherin men than and in women. This study systematically reviewed population-based studies of AF 
published from 1980 to 2010 from the 21 Global Burden of Disease regions to estimate global or 
regional prevalence, incidence, and morbidity and mortality related to AF. The estimated number of 
individuals with AF globally in 2010 was 33.5 million (20.9 million men [95% uncertainty interval 
(UI), 19.5–22.2 million] and 12.6 million women [95% UI, 12.0–13.7 million]). Burden associated 
with AF, measured as disability-adjusted life-years, increased by 18.8% (95% UI, 15.8–19.3) in men 
and 18.9% (95% UI, 15.8–23.5) in women from 1990 to 2010. The overwhelming majority of studies 
of patients with AFare in line with a male predominance. The Active-W (Atrial Fibrillation 
Clopidogrel Trial withIrbesartan for Prevention of Vascular Events) Trial 
34
which evaluated patients 
with AF in 526 centres and 15 countries had males accounting for more than 67% of their cohort. 
Similarly, in the ROCKET-AF study (Rivaroxaban Once daily oral direct factor Xa inhibition 
compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial 
Fibrillation) 
46
which studied 6983 patients taking warfarin for AF across 45 countries, a 61% male 
predominance was observed. 
In AF, females confer higher risk for stroke than male patients. This is validated by the CHA2DS2-
Vascscore (Table 2) where female gender accounts one point in the risk assessment tool. 
Femaleswere identified as a significant factor associated with poor quality of anticoagulation (as 
evaluated by the TTR) in patients with AF. A study evaluating factors affecting quality of 
anticoagulation control among patients with AF on warfarin(The SAMe-TT2R2 Score)
31
which 
evaluated patients from the AFFIRM trial
52
, found female gender as a significant factor (p<.0001) 
associated with poor quality of anticoagulation. 
There is little data on gender association with quality of anticoagulation in patients with prosthetic 
heart valves. 




In our study population, of the 177 patients being anticoagulated with warfarin for either non-valvular 
AF or prosthetic heart valves, the majority were females (n = 122, 68.9%). In the AF subgroup, 
females accounted for 63(65.6%) of the 96 patients and in the subgroup of patients with prosthetic 





Table 12:Distribution of anticoagulated patients at Mahatma Gandhi Memorial Hospital 
by gender. 
 Male, n (%) Female, n (%) 
   
Sample population (N=177) 55 (31.1%) 122 (68.9%) 
   
AF cohort (n=96) 33 (34.4%) 63 (65.6%) 
   
Valve prosthesis (n=81) 22 (27.2%) 59 (72.8%) 
   
 
Comparisons between male patients (n=55) and female patients (n=122) in the sample population 
(Figure 8) showed no significant difference in the mean percentage timebelow range(M= 47.4; 
SD=26.1; M=46.5,SD=28.4)[t (175) =.191, p-.849], mean percentagetime above range(M=24.2; 
SD=14.9; M=23.7; SD=17.1) [t (175) =.175,p-.854], mean percentage time with an INR value greater 
than 4.00(M=10.2; SD=11.1; M=11.4; SD=11.1) [t (175) = -.665, p-.507], mean percentage TTR 
using the Direct method (M=27.9; SD=22.0; M=29.5; SD=21.8)[t (175) = -.439,p-.661] and mean 





Figure 8: Distribution by gender within the sample population (N=177) for 




Comparison of means of male patients (n=33) and female patients (n=63) in the AF cohort(Figure 9) 
showed no significant difference in the mean percentage timeabove range(M=25.5; SD=14.9; 
M=29.8; SD=18.2) [t(94) = -1.177, p-.242], mean percentage time with anINR value greater than 
4.00(M=7.5; SD=10.3; M=9.9; SD=11.3) [t (94) = -1.045, p-.299], mean percentage TTR using the 
Direct method(M=38.0; SD=21.3; M=43.9; SD=18.5) [t (94) = -1.4,p-.165] and the mean percentage 
TTR determined by the Rosendaal method (M=43.2; SD=20.4; M=45.1; SD=17.5) [t (94) = -.469,p-
.640] respectively. 
However, male patients in the AF cohort (M=35.5; SD=23.8) spent significantly more time below 




Figure 9: Distribution by gender within the AF cohort(n=96) for mean percentage time in 







The comparison of male patients (n= 22) and female patients (n= 59)in the valve prosthesis cohort 
(Figure 10)showed no significant difference in the mean percentage time below range(M= 65.2; 
SD=18.4; M=68.6, SD=20.6) [t (79) = -.668, p-.506], mean percentage time above range(M=22.3; 
SD=15.0; M=17.2; SD=13.3) [t(79) = 1.486,p-.141], mean percentage time with an INR value greater 
than 4.00 (M=14.3; SD=11.3; M=12.9; SD=10.8) [t (79) =.485,p-.629], mean percentage TTR derived 
by the Direct method (M=12.8; SD=12.5; M=14.1; SD=12.9) [t (79) =.637, p-.684] and the mean 





Figure 10: Distribution by gender within the valve prosthesis cohort (n=81) for mean 










Unlike most other studies of patients on oral anticoagulation, the distribution by gender in our sample 
population is glaringly different as females represent the majority of this study population. Many of 
the studies conducted globally have constituted patients largely from out of South Africa. In the 
ROCKET-AF trial
46
, only 124(2%) of the 6983 patients were from South Africa; 98 patients of the 
6706 patients represented South Africa in the ACTIVE-W study
34
. The prevalence and epidemiology 
of AF in Africa, particularly South Africa is largely understudied as compared to other regions and 
this most likely accounts for the disparity in gender association. One study in Cape Town, South 
Africa, which evaluated warfarin utilisation and monitoringrecords in two hospitals with different 
patient groups
53
, conducted a chart audit on 111 patients using warfarin. The findings in this local 
study are similar to that of ours with regard to gender frequency with the majority of the patients 
being female (62.5% and 80.6% in the two centres respectively). Another local study of patients 
attending an anticoagulation clinic in Cape Town, evaluated 136 patients on warfarin, of which the 
majority(56.6%, n=77) were female. One possible reason for the gender distribution disparity in South 
African populations studied may be explained in the general attendance patterns for medical care, 
where males have been well shown as having less frequent attendance to medical screening and 
treatment as compared to females in studies involving a number of other chronic diseases. 
Overall, patients in our study population (N=177), had no statistically significant gender bias with 
regard to time in range and time out of range. The separate cohort of patients being anticoagulated for 
prosthetic heart valves (n=81) also did not reveal significant differences between males and females. 
In the AF subgroup (n=96), however, we found male patients spent significantly more time under –
anticoagulated than female patients and less TTR than female patients, albeit with no significant 
difference in TTR. These findings are not in line with the findings of other global studies.In the study 
by Apostolakiset al., female gender was strongly associated (p<.001) with poor 
anticoagulation
31
.Dlottet al., who identified 138,319 individuals with AF, found females had lower 
TTR than males (-1.3%, 95% CI: -1.5% to -1.0%)
48
. Similarly Rose et al., in their US study, enrolled 
3396 patients from 101 community-based practices in 38 states, found a trend of poorer 
anticoagulation quality in females. In their study, the group with excellent INR control had the lowest 
proportionof females (37.9%), followed by the good control group(42.6%), with the highest 
proportion of females in the poorcontrol group (46.5%; p<.001 for trend)
9
. 
The reason for this disparity, in our clinical setting could be explained by the overall socio-economic 
status of the region, where usually, males are sole bread winners and as a result have a tendency to 
follow-up less frequently and demonstrate poorer adherence to treatment due to commitment to 
vocational duties. The implications of these findings in accordance with global study findings suggest 
that in our region, both males and females have equally high risk for poor anticoagulation when 




6.2. Age association with time in range and time out of range 
The prevalence of AF increases with age. The Global Burden of Disease study in 2010 evaluated the 
epidemiology of AF byanalysing population-based studies of AF published from 1980 to 2010 
fromthe 21 Global Burden of Disease regions. In this study higher rates of AF in older age groups 
were observed. Men aged 75 to 79 years had double the prevalence rate compared with men who were 
65 to 69 years of age and a greater than 5-fold higher prevalence compared with men who were 55 to 
59 years of age
3
. Data from the Framingham study 
54
 and a study by Psatyet al.,which evaluated 5201 
patients who were at least 65 years old, found the onset of AF to be strongly associated with age. For 
men who were 65 to 74 and 75 to 84 years old, the incidences were 17.6 and 42.7, respectively, and 
for women, 10.1 and 21.6 events per 1000 person-years
55
. A cross-sectional study by Go, A.S et 
al.,evaluated 17974 patients with AF and found that prevalence increased from 0.1% among adults 
younger than 55 years old to 9.0% in persons aged 80 years or older
56
. 
An older age is a well validated risk factor for stroke in patients with non-valvular AF. The 
CHA2DS2-Vascscoring tool for risk of stroke uses an age of 65 years or older as a risk predictor with 
patients 75 years or older inferring even higher risk (Table 2). The Framingham study found that for 
persons aged 80-89 years, AF was the sole cardiovascular condition to exert an independent effect on 
stroke incidence (p<.001). The study found that the attributable risk of stroke for all cardiovascular 
contributors decreased with age except for AF, for which the attributable risk increased significantly 
(p<.01), rising from 1.5% for those aged 50-59 years to 23.5% for those aged 80-89 years
8
. 
In addition to older age being a risk for AF itself, as well as conferring increased risk for stroke in AF, 
age has been found to be a factor in affecting the quality of anticoagulation. Unlike the risk of AF or 
that of stroke, a younger age is associated with a negative quality of anticoagulation. 
Apostolakiset al.,
31
 evaluated clinical factors associated withTTR in patients from the cohort from the 
AFFIRM trial which conducted a randomised, multicenter comparison of rate versus rhythm treatment 
strategies in 4060 patients with atrial fibrillation and a high risk of stroke or death. This study showed 
a negative TTR association with younger patients :age less than 50 years old (p <.0001), age 50 to 60 
years old (p<.02) and included an age less than 60 years old as a significant factor associated with 
poor TTR or quality of anticoagulation in patients treated for AF 
52
. 
Rheumatic heart disease as a result of recurrent rheumatic fever is still prevalent in South Africa and 
other developing countries and accounts for the majority of patients requiring valve replacement 
surgery as compared to developed regions where age associated and degenerative changes is the 
common aetiology. A reasonable proportion of patients being anticoagulated for prosthetic heart 
valves in South Africa are therefore much younger than patients being anticoagulated for AF. There is 
little data relating to the quality of anticoagulation across different age categories in patients being 
anticoagulated for prosthetic heart valves. 
We evaluated the patients in our study population and the subgroups of AF and valve prosthesis for an 
association with time in range as determined by the TTR and the time out of range, which was further 









The mean age of our study population was 54.2 years (SD=17.6). The mean age in the AF sub-cohort 
(64.7 years, SD=11.3) was higher than in the valve prosthesis cohort (M=41.83 years, SD=15.7. In the 
AF subgroup, 53.1% (n=51) of the patients were 65 years or older, of which 17 (17.7%) were aged at 
least 75 years old and therefore predicted higher stroke risk. In the subgroup of patients with 
prosthetic heart valves, the majority of patients were less than 60 years old (67 patients and 82.7%) 
(Table 9). 
In the AF subgroup of patients (Figure 11), the mean percentage time below range was highest for 
patients within the 65 years to less than 75 years old age group (M=31.8; SD=20.5) as compared to 
patients who were 75 years or older (M=30.2; SD=16.5) and patients who were less than 65 years old 
(M=26.8; SD=20.7) (Figure 11). These differences were however not statistically significant within 
the three groups [F (2, 93) =.616,p-.542]. 
Patients less than 65 years old spent the most time above range (M=30.7, SD=17.4)compared to the 
65 to less than 75 years old group (M= 27.5; SD=15.7) and the 75 years or older group (M=23.9; 
SD=19.4). The difference in means was not significant [F (2, 93) = 1.056, p-.352]. 
The 65years old to less than 75 years old group had the highest mean time with an INR value in 
excess of 4.00 (M=10.3; SD=10.9) compared to the 75 years or older group (M=9.8; SD=13.4) and 
the less than 65 years old group (M=7.9; SD-10.2). Analysis by one way ANOVA showed that the 
difference was not significant [F (2, 93) =.487, p-.616]. 
The age group with the highest mean percentage TTR using the Direct method was the 75 years or 
older group (M=44.7; SD=16.5) compared to the less than 65 years old group (M=41.7; SD=20.4) and 
the 65 to less than 75 years old group (M=40.7; SD=20.4). The difference was not statistically 
significant [F (2, 93) =.232, p-.794]. 
On analysis of the TTR using the Rosendaal method, the less than 65 years old group had the highest 
mean TTR (M=45.0; SD=16.9) compared to the 75 years or older group (M=44.5; SD=17.2) and the 
65 to less than 75 years old group (M=43.8; SD=21.3), however the difference between the age 














Figure11: Distribution by age within the AF cohort (n=96) for mean percentage time in 
range and out of range. 
 
 
Overall, patients in the valve prosthesis cohort (Figure 12) spent the majority percent time below 
range, however the differences between the age groups was not statistically significant [F (5, 75) = 
1.115, p -.360]. 
There was no statistically significance difference in means between the age groups for the condition 
of mean percentage time above range and time with an INR value greater than 4.00. [F (5, 75) = 
1.553, p -.184] and [F (5, 75) = 2.199, p -.063] respectively. 
Similarly, TTR using both the Direct and Rosendaal methods was not significant between the 









Figure 12: Distribution by age within the valve prosthesis cohort for mean percentage time 




Our primary objective was to evaluate the TTR and overall, patients in both cohorts i.e. AF and valve 
prosthesis both demonstrated low mean percentage TTR across all age groups. Patients who were 75 
years and older in the AF cohort, showed the best mean percentage TTR using the Direct method, 
however with analysis by the Rosendaal method, the youngest age category i.e. patients less than 65 
years old had the highest mean percentage TTR. This difference was not statistically significant. The 
findings in our study are different from Dlottet al., who studied anticoagulation control in 138 319 
individuals and reported a significantly (p<.001) better mean TTR in patients 75 years or older 
(53.9%) than those who were 45 years or younger (45.5%). However, the study by Dlottet al., 
reported a mean age of 74 years old and included patients who were being monitored for less than 
sixmonths
48
. Another study that reported better TTR with older patients was the STABLE study that 
evaluated quality of anticoagulation in 29457 patients who performed home monitoring. They found 
that patients aged 65 to less than 75 years old (71.5%) had higher TTR than the younger population of 
46 to 64 years (67.0%). Patients who were 75 years or older also achieved relatively high TTR (75-79 






In our study, the AF cohort demonstrated no statistically significant difference age categories and is 
line with the findings of Rose et al.,who studied 3396 patients across 101 community practices and 
found similar mean ages for patients with TTR less than 65%, TTR from 65 to 75% and TTR better 
than 75%
9
. Similarly, Gallagher et al., in a study of 27,458 warfarin-treated patients reported no 
substantial difference in TTR by age
47
. 
We note with concern, however, that patients with higher bleeding risk (patients older than 65 years 
old) in accordance with the HASBLED predictor of bleeding (Table 5)in the AF cohort demonstrated 
the most time with an INR value greater than 4.00 which confers an added bleeding risk. This may be 
attributed to altered pharmacodynamics and altered enzymatic activity in the elderly and possibly due 
to concomitant drug interactions that the elderly are more likely to be taking. These details were 
beyond the scope this study, however, and further evaluation needs to be undertaken. 
Our study of patients in the valve prosthesis cohort, demonstrated poor TTR throughout the different 
age categories and for all conditions studied, the mean percentage time was comparable across the age 
groups with no significant differences for both TTR and time out of range. 
 
6.3. Association of frequency of INR testing with time in range and time out of range 
There is substantial evidence suggesting more frequent INR testing is associated with improved 
quality of anticoagulation and reduced risk of adverse events. The Home INR Study (THINRS), 
which evaluated patients being anticoagulated for both AF and prosthetic heart valves found improved 
TTR in patients tested more frequently
37
. Similarly, the STABLE trial which was a retrospective 
analysis of 29457 patients with multiple indications for warfarin therapyevaluated patients who were 
tested more frequently to have a higher percentage TTR
38
.The evidence that more frequentINR 
monitoring translates to more effective control through dose adjustment is well documented, however, 
very frequent testing is not feasible in patients who do not have point-of-care devices and rely on 
clinic or hospital visits. Generally, most clinicians evaluate INR levels at least every 28 days, and this 
is largely based on expert opinion and clinician experience. However, the study by Rose et al., found 
that longer INR monitoring intervals were associatedwith improved INR control
9
and this was in line 
with studies in England where TTR in excess of 65% with testing frequency as few as 12 weeks 
57
. 
They therefore concluded that a variable follow-up period based on recent INR results should replace 
fixed testing periods. 
In our patient population, we evaluated the impact of frequency of INR testing (if any) on TTR and 
time out of range (sub-categorised as time below range, time above range and time with an INR level 
greater than 4.00). 
 
6.3.1. Results 
In the entire cohort of patients (N=177), the mean number of days between INR testing was 33.3 days 
(SD=12.0).The majority of patients (42.4%, n=75) had INR testing from 28 to 32 days apart. More 
than one-third (34.5%, n=65) of the patients studied were tested more than 32 days apart and 23.2 % 




In the AF subgroup, the mean number of days between INR testing was 31 days (SD=6.8) and 36 
(37.5%) of the 96 patients had an INR testing frequency of 28 to 32 days apart. Thirty-one (32.3%) of 
the patients were tested more frequently and the remaining 29 (30.2%) of the patients were tested 
more than 32 days apart (Table 9). 
In the subgroup of patients with prosthetic heart valves, the mean number of days between tests was 
36 days (SD=15.8). While the majority (48.1%, n=39) of the patients in this subgroup were tested 
from 28 to 32 days apart, only 12.3% (n=10) had INR testing less than 28 days apart and almost 40% 
(n=32) of the patients were tested less frequently (Table 9). 
Results for the entire sample (Figure 13) showed that patients who had INR monitoringless than 28 
days apart (M=27.9; SD=17.4) spent the most amount of time below range followed by patients who 
had monitoring from 28 to 32 days apart (M=24.9; SD=15.0). Patients being monitored on average 
more than 32 days apart (M=19.8; SD=16.9) had the least percentage of time below range. This 
difference was statistically significant [F (2, 174) = 4.992, p -.008]. However, post hoc analysis 
showed differences only between patients who were monitored less than 28 days apart and those 
monitored more than 32 days apart (p-.005). Time spent below range between patients monitored less 
than 28 days apart and those monitored between the 28 days to 32 days apart group were not 
statistically significant, nor was the time below range between the 28 to 32 days and more than 32 
days apart groups (p-.190 and p-.202 respectively). 
The percentage of time above range was also significantly different between patients depending on 
frequency of INR testing [F (2, 174) = 3.347, p-.037]. Post hoc analysis revealed significant 
differences only between the group monitored less than 28 days apart (M=27.9; SD=17.4) and more 
than 32 days apart (M=19.8; SD=16.9) (p-.038). Neither comparisons between the less than 28 day 
group and 28 to 32 days group (M=24.9; SD=15.0) were significant (p-.606), nor was the 28 to 32 day 
group and more than 32 days group (p-.164). 
The mean percentage time spent with an INR value greater than 4.00 was not significant [F (2, 174) = 
1.405, p-.248] between the less than 28 days apart group (M=12.0; SD=13.7), the 28 days to 32 days 






Figure 13: Distribution by frequency of INR testing within the sample population (N=177) 
for mean percentage time in range and out of range. 
 
 
The mean TTR assessed by both the Direct method and the Rosendaal method was inversely related 
to the frequency of monitoring, with the group of patients being monitored less than 28 days apart 
(M=34.8; SD=23.0 and M=35.9; SD=23.5) having higher percentages TTR than the group monitored 
from 28 to 32 days apart and more than 32 days apart (M=28.4; SD=20.5 and M=30.6; SD=19.1) 
respectively. Similarly the group of patients being monitored from 28 to 32 days apart had higher 
percentage of TTR than those patients being monitored more than 32 days apart (M= 25.9; SD=22.3 
for the Direct method and M=26.4; SD=23.8 for the Rosendaal method). However analysis by one 
way ANOVA for both the Direct method and the Rosendaal method revealed this difference as not 
significant. [F (2, 174) = 2.120, p-.123] and [F (2, 174) = 2.324, p-.101] respectively. 
 
Analysis of the AF cohort (n=96) alone and it was found that there was no statistical significance for 
the conditions of mean percentage time below range (p-.613), above range (p-.792), time with an INR 
value of greater than 4.00 (p-.911) and TTR using the results of the Direct (p-.899) and the Rosendaal 






Figure 14: Distribution by frequency of INR testing within the AF subgroup (n=96) for 
mean percentage time in range and out of range. 
 
 
Overall in the valve prosthesis cohort (Figure 15), the majority of time was spent below range. When 
categorised against mean days between INR tests (Figure 15), there was a significant difference 
between the patients in the different groups [F (2, 78) = 3.673, p-.030]. 
Post hoc analysis using the Tukey HSD statistic test revealed a significance difference (p-.023) 
between patients who had INR monitoring 28 to 32 days apart (M=61.9; SD=18.9) and patients who 
were monitored on average more than 32 days apart (M=74.4; SD=20.7). The difference in time spent 
below range when comparing the group of patients who are monitored less than 28 days apart 
(M=68.7; SD=16.2) and those being monitored from 28 to 32 days apart or patients being monitored 







Figure 15:Distribution by frequency of INR testing within the valve prosthesis subgroup 
(n=81) for mean percentage time in range and out of range. 
 
The mean percentage of time spent above range was significantly different across the different groups 
[F (2, 78)= 3.6669, p-.030] with patients monitored less than 28 days apart (M=22.4; SD=13.6) 
having a higher percentage time above range than those patients being monitored from 28 to 32 days 
apart (M=21.8; SD=13.9) and the group of patients monitored more than 32 days apart (M=13.6; 
SD=12.7) having the least percentage time above range. Post hoc analysis revealed asignificant 
difference only between the group being monitored from 28 to 32 days apart and those patients being 
monitored more than 32 days apart(p-.035). Comparisons between patients monitored less than 28 
days apart and patients monitored from 28 to 32 days apart and more than 32 days apart was not 
significant. (p-.991 and p-.177 respectively) 
In line with a significant difference between groups for percentage time spent above range, the mean 
percentage time spent with an INR value greater than 4.00 was also significant in the valve prosthesis 
cohort [F (2, 78) = 4.372, p-.016], between the group of patients with monitoring less than 28 days 
apart (M=18.8; SD=13.2), patients monitored from 28 to 32 days apart (M=15.2; SD=10.6) and 
patients monitored more than 32 days apart (M=9.4; SD=9.3). Post hoc analysis revealed significant 
difference only between patients monitored less than 28 days apart and more than 32 days apart(p-




to 32 days and patients monitored from 28 to 32 days apart and those patients with monitoring more 
than 32 days apartwas not statistically significant (p-.600 and p-.052 respectively). 
On assessment of the mean percentage TTR by both the Direct and Rosendaal methods the group of 
patients monitored from 28 to 32 days apart (M=16.3; SD=11.9 and M=17.4; SD=11.2) spent more 
TTR than the group monitored more than 32 days apart(M=12.3; SD=14.5 and M=10.4; SD=12.7) 
who in turn had more TTR than patients being monitored less than 28 days apart(M=8.9; SD=7.4 and 
M=9.5; SD7.6) respectively. However statistical significance between the Direct method [F (2, 78) = 
1.755, p-.180)] and the Rosendaal method [F (2, 78) = 3.975, p-.023] differed. The significance of the 
condition for TTR by theRosendaal method only differed between the group tested from 28 to 32 days 
apart and the group monitored more than 32 days apart(p-.034). The comparison between patients 
monitored less than 28 days apart with patients monitored less frequently was not statistically 
significant (p-.137 against the 28 to 32 days group and p-.975 when compared to patients monitored 
more than 32 days apart). 
 
6.3.2. Discussion 
Overall, more than one-third of our study population had INR testing more than 28 days apart. In our 
study setting, patients are supplied with a maximum of 28 days of warfarin before the prescription has 
to be renewed following a clinician review of the patient and the INR value. Therefore, patients who 
are monitored less frequently have an implied period without anticoagulation. Patients who had recent 
suboptimal or supratherapeutic INR values are usually followed up prior to 28 days. 
This may explain why patients monitored less frequently demonstrated less time above range and less 
time with an INR value greater than 4.00 compared to those patients monitored less than 28 days 
apart. Interestingly, however, patients in our study who were monitored less than 28 days apart spent 
more time below range than patients monitored less frequently. This may be because the group of 
patients monitored more frequently had been previouslyidentified as having 
suboptimalanticoagulationwhich accounts for their more frequent monitoring. This is in line with the 
findings from Dlottet al., a study of 138319 individuals with AFwhich found a nonlinear association 
between INR testing frequency and TTR
48
; INR testing frequency was positively associated with TTR 
among patients with fewer than 14 INR tests peryear, but inversely associated with TTR among those 
with more frequent testing. This patternlikely reflects increased testing among individuals with poor 
INR control. The ORBIT (Outcomes Registry for Better Informed Treatment of Atrial 
Fibrillation)trial evaluated 5210 patients with AF on warfarin and treated at 155 sites, concluded 
similar findings of patients in their study with subtherapeutic or supratherapeuticvalues having their 
INR level tested more frequently
40
. 
Our primary objective was the TTR, and our study sample demonstrated an improved anticoagulation 
in patients monitored more frequently than those monitored less frequently which is in line with the 
findings from the THINRs 
37
 trial and the STABLE 
38
 study, both of which concluded more frequent 
testing was associated with improved TTR. Similarly, results from the ROCKET-AF (Rivaroxaban 
Once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of 
strokeand Embolism Trial in Atrial Fibrillation) study which evaluated 6983 patients taking warfarin, 
recruited from 45 countries found that regions with the lowest individual TTR had INR distributions 
shifted toward lower INR values and had longer inter-INR test intervals
46
.In our study population 




the frequency of INR testing and therefore likely contributed less to the overall findings than patients 
with prosthetic valves. 
In line with the explanation of drug therapy duration for a maximum of 28 days, patients with 
prosthetic valves showed significantly less time above range and less time with an INR value greater 
than 4.00 if they were monitored less frequently. This may also explain the higher mean percentage 
time spent below range in these patients. 
 
 
6.4 Association of INR target range and time in range and time out of range 
 
The target therapeutic range for any patient on warfarin is determined by finding the balance of 
achieving a sufficient anticoagulation effect without substantially increasing the risk of haemorrhage. 
In AF, several studies have attempted to determine the ideal range (Table 4). Hyleket al., studied a 
cohort of 13559 patients with non-valvular AF and concluded among these patients 
thatanticoagulation resulting in an INR of 2.0 or greater reduces not only the frequency of ischaemic 
stroke but also its severity and the risk of death from stroke. Moreover their findings provided further 
evidence against the use of lower INR target levels in patients with AF and indeed the accepted target 
range for AF is from 2.0 to 3.0
23
. 
The target INR range for patients with prosthetic heart valves are determined by various factors. Two 
important categories are the degree of valve thrombogenecity(Table 13)and the presence or absence of 
other patient risk factors for thrombo-embolism. These factors determine the target INR range for any 
patient being anticoagulated with prosthetic mechanical heart valves (Table 6). 
 
 
Table 13: Valve thrombogenicity and types of prosthetic heart valves 
Valve thrombogenicity 
Low Medium High 
Carbomedics (aortic position) Bjork-Shiley Starr-Edwards 
Medtronic Hall Other Bi-leaflet valves Omniscience 
St Jude Medical (without Silizone)  Lillehei-Kaster 
 
There is sufficient evidence of differing quality of anticoagulation with target ranges. Rose et al., 
studied 3396 patients from 101 community-based practices and concluded TTR is affected by the 
target INR range
9
. In that study, 127 patients had a target ranges below 2.0 and spent42.7% of time 
with an INR below 2.0, comparedto 18.8% for patients with the standard target range(p<.001). These 
patients also spent significantly less time than the group with standard target ranges with an INR 




their study had a significantly (p<.001) lower mean TTR (52.5%) than warfarin users with a normal 
INR target range (67.5%). 
We described the quality of anticoagulation in our population according to the differing target INR 
ranges and assessed for any association. 
 
6.4.1. Results 
All patients in the AF subgroup (n=96) had INR target ranges of 2.0 to 3.0. In the subgroup of patients 
with mechanical heart valve prostheses (n=81), target ranges were categorised according to valve 
thrombogenicity and patient risk factors (Table 13). The three target INR ranges were 2.5 to 3.0 
(n=14, 17.3%), 3.0 to 3.5 (n=21, 25.9%) and 3.5 to 4.0 (n=46, 56.8%). 
 
Table 14: Distribution of patients in the valve prosthesis subgroup according to target INR 
range. 






Target INR Range - 2.5-3.0 14 17.3  
Target INR Range - 3.0-3.5 21 25.9  
Target INR Range - 3.5-4.0 46 56.8  
Total 81 100.0  
 
 
One way ANOVA of the valve prosthesis cohort (n=81) showed statistically significant differences 
for the conditions of mean percentage time below range [F (2, 78) = 19.953, p - <.001], above range 
[F (2, 78) = 6.609, p -.002] and TTR for both the Direct [F (2,78) = 14.499, p - <.001] and Rosendaal 
[F (2, 78) = 26.099, p - <.001] methods (Table 15). 
Analysis of differences between the target INR ranges and percentage time with an INR value above 
4.00 was not statistically significant(p-.112) when limited to the valve prosthesis cohort, however 
when analysed with inclusion of the AF subgroup there was a statistical difference demonstrated (p-
.014). 
A Tukey post hoc test revealed time below range was statistically significant between patients with 
the target range 2.5 to 3.0 (M=42.6; SD=20.8) and target range 3.0 to 3.5 (M=70.1; SD=17.7) (p- 
<.001) and target range 2.5 to 3.0 and 3.5 to 4.0 (M=74.2; SD=14.4) (p- <.001). The target range 3.0 
to 3.5 compared to 3.5 to 4.0 was not statistically significant (p-.623). 
A TukeyHSD post hoc test showed the most time spent above range was in the group with a target 
INR range of 2.5 to 3.0 (M=29.9; SD=15.8) followed by the group with an INR target range of 3.0 to 
3.5 (M=17.9; SD=14.5) and the difference between these groups were statistically significant (p-




(M=15.5; SD=11.3) was also statistically significant (p-.001). Comparison for the condition time 
above range for the target INR range 3.0 to 3.5 and 3.5 to 4.0 was not significant (p- 1.00). 
 
Table 15: Distribution by target INR range for time in range and time out of range. 





















Mean % Time Above range 
p<.001 
28.4† 29.9‡ 17.9 15.5 
Mean % Time INR > 4.00 
p =.014 
9.1‡ 9.6 11.1 15.5 
Mean % TTR-Direct 
p<.001 
41.9*† 28.2† 12 10.3 
Mean % TTR-Rosendaal 
p<.001 
44.5*† 30† 12.1 9.4 
 
*p<.05when compared to target groups 2.5-3.0 by Tukey HSD post hoc analysis 
† p<.05 when compared to target groups 3.0-3.5 and 3.5-4.0 by Tukey HSD post hoc analysis 
‡ p <.05 when compared to target group 3.5-4.0 by Tukey HSD post hoc analysis 
 
 
Patients with a target INR range of 2.5 to 3.0 had the highest TTR for Direct method (M=28.2; 
SD=14.8) and the Rosendaalmethod (M=29.9; SD=13.4) followed by the target INR range of 3.0 to 
3.5 (M=11.9; SD=13.1 and M=12.1;SD= 9.4 respectively). The group of patients with a target INR of 
3.5 to 4.0 had the least TTR when evaluated by both the Direct(M= 10.3; SD=8.5) and Rosendaal 
(M=9.5; SD=7.8) methods. Post hoc analysis of the differences between groups with a target INR 
range of 2.5 to 3.0 and 3.0 to 3.5 and 3.5 to 4.0 was statistically significant (p<.001 for both 
comparisons) for the conditions of TTR using the Direct method as well as the Rosendaal method. 
Comparison between the target INR range of 3.0 to 3.5 and 3.5 to 4.0 was not significant for either the 
Direct method (p-.836) or the Rosendaal method (p-.539). 
Patients with AF entirely constituted the group with target INR range of 2.0 to 3.0. This subgroup had 
performed strongly statistically significantly better than patients with higher target ranges across all 
conditions and was the only subgroup to show statistical difference for the time with an INR greater 
than 4.00 (p-.007) when compared to patients targeted for the range 3.5 to 4.0. 
 
6.4.2. Discussion 
In our study population of patients with prosthetic heart valves, significant differences in the quality 
of anticoagulation when compared by the target INR range was demonstrated. Patients with the lowest 
target range had a superior TTR than patients with higher targets. This is contrary to the findings from 
the study by Rose et al.,
9




than those with normal INR target range
9
. However, the study by Rose et al., was conducted on 
patients with AF and not with prosthetic valves and the target INR ranges were lower than for the 
patients with valve prostheses in this study. Nevertheless we found similarly, that patients in this 
study with the lowest target rangedemonstrated the least time below range. However, this subgroup of 
patients also demonstrated the most time above range which is not in line with the findings by Rose et 
al. 
These findings confirm that patients with low target ranges are easier to achieve effective 
anticoagulation but are also at risk for over-anticoagulation and therefore bleeding as compared to the 
subgroup of patients with higher INR target ranges. It is noteworthy to mention that patients with the 
highest targeted range risk imply the presence of risk factors and it is worrying that these patients 
demonstrated the least efficient anticoagulation. 
The group of patients with the lowest target INR (2.0 to 3.0) in our study population was constituted 
entirely by the AF subgroup and performed statistically better across all conditions versus patients 
with higher target ranges. 
There is extensive literature recommending the target INR ranges and that these should be rigidly 
adhered to. Indeed, the study by Hyeketal., concluded that their study provided further evidence 
against the use of lower INR target levels in patients with AF
23
. In patients with prosthetic heart 
valves, inadequate anticoagulation is a major risk factor for valve obstruction by thrombus. As such, 
the findings in this study should not be used as motivation for adjusting target ranges in patients 
requiring anticoagulation. It does however add clinical value in identifying that patients with the 










Warfarin, as an anticoagulant is used to prevent thrombo-embolism in patients with AF and 
mechanical prosthetic valves. One important consequence of anticoagulation is the risk of bleeding. 
Non-haemorrhagic complications of warfarin include skin necrosis, however this is rare. 
AF is a common heart condition and indeed the most common heart rhythm abnormality. According 
to the 2010 Global Burden of Disease study evaluating the epidemiology of AF, the estimated number 
of individuals with AF globally has increased. 
3
. 
AF has been evaluated as an independent risk factor for stroke and this risk increases with advancing 
age.
8
. These findings have been discussed in Chapter 1.2 earlier in this work. 
7
. 
There are numerous studies proving risk of stroke reduction with anticoagulation (Table 4). When the 










) major studies were 
evaluated in a pooled analysis, it was demonstrated that warfarin attributed a 69% stroke risk 
reduction (Table 4). 
The quality of anticoagulation strongly correlates with the risk of thrombo-embolism or stroke. The 
ACTIVE-W trial 
34
 found the benefit of stroke prevention with warfarin over aspirin and clopidogrel 
was lost if the TTR was less than 58%. The study by Wan et al.,evaluated anticoagulation control and 
prediction of adverse events in patients with AF by a systemic review of 47 studies. They found that 
TTR negatively correlated with major haemorrhage (r= -0.59; p-0.002) and thrombo-embolic rates (r= 
-0.59; p-0.01). This effect was significant in retrospective but not in randomised controlled trials 
(Figure 16). For retrospective studies, a 6.9% improvement in the TTR significantly reduced major 
haemorrhage by one event per 100 patient-years of treatment.Furthermore, they concluded that a 12% 
increase in TTR can reduce the thrombo-embolic rate by one event per 100 patient-years 
45
.Data from 
the ROCKET-AF trial, evaluated the relationship between TTR and the comparative treatment effects 
of rivaroxaban and warfarin and found that patients in the highest quartile of TTR had a lower event 
rate per 100 person-years than patients in the lowest quartile of TTR (1.3 vs 2.0) when analysing 


















TTR versus major haemorrhage rate (n=9), correlation: r= -0.78; P-.006; linear regression: Y (major 
haemorrhage rate) =11.716-0.145X (TTR), R2=0.61; P=.01. TTR versus thrombo-embolic rate (n=5), 
correlation: r= -0.88; P=.026; linear regression: Y (thrombo-embolic rate) =6.943- 0.084X(TTR), R2=0.77; 
P=.05. 
Figure 16: TTR versus adverse events for retrospective studies (copied from Wan Y, et al., 
Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: 




The risk of haemorrhage has been well described in patients using oral anticoagulation. Since the 
introduction of the non-vitamin K oral anticoagulants there have been multiple trials assessing the 
bleeding risks. The International Society of Thrombosis and Haemostasis (ISTH) sought to unify the 
definition of major bleeding and the committee had agreed upon the following characteristics to fulfil 
the definition of major bleeding
59
: 
1.  Fatal bleeding, and/or 
2. Symptomatic bleeding in a critical area or organ, such asintracranial, intraspinal, intraocular, 
retroperitoneal, intra-articularor pericardial, or intramuscular with compartmentsyndrome, 
and/or 
3. Bleeding causing a fall in haemoglobin level of 2 g/dL(1.24mmol/L) or more, or leading to 
transfusion of twoor more units of whole blood or red cells. 
Levine et al., described the haemorrhagic complications of anticoagulant treatment. They noted major 
determinants of vitamin K antagonist-induced bleeding to be the intensity of the anticoagulant effect, 






There have been various studies evaluating bleeding risk in patients being anticoagulated with 
warfarin which has yielded a number of risk assessment tools. The most accepted bleeding risk tool is 
the HASBLED score (Table 5). In a meta-analysis by Bloomfield et al., which reviewed 35 studies 
and 453 918 participants evaluated the risk factors for serious bleeding in patients on oral 
anticoagulation. They demonstrated the factors most consistently predicting an increased risk of 
bleeding were age more than 75 years, first months following warfarin initiation, concomitant 
medication use (particularly aspirin use), co-morbid conditions, history of gastrointestinal bleeding 
events or diabetes, primary indication for taking warfarin was a valvecondition, genetic factors like 
variation in the CYP2C gene, and bleeding risk indexes
39
. 
Since the introduction of the non-vitamin K oral anticoagulants, there have been numerous 
comparative studies evaluating the adverse events surrounding patients with AF and on VKAs (Table 
16). These studies have provided valuable information toward evaluating adverse events in these 
populations. 
 
Table 16: Evaluation of stroke or systemic embolism and major bleeding as per 
comparative studies between warfarin and the non-vitamin K oral anticoagulants. 





(N=18133) Warfarin 1.7% per year 
1.55% per year 
1.11% per year 
3.46% per year 
2.74% per year 


















 (N=18201) Warfarin 1.60% per year 
 
1.27% per year 
3.09% per year 
 







Warfarin 1.50% per year 
1.18% per year 
1.61% per year 
3.43% per year 
2.75% per year 




Prosthetic valve thrombosis is a rare though devastating complication of prosthetic heart valves. The 
incidence is higher for mechanical than for biological heart valves, right-sided more common than 
left-sided and mitral more common than aortic.Valve thrombosis is most often encountered in patients 
with mechanical valves and inadequate antithrombotic therapy. The incidence of obstructive valve 
thrombosis varies between0.3% and 1.3% per patient-year in patients with mechanical 
valves
21,61
.Serious complications in patients with prosthetic heart valves occur at a rate of 2% to 3% 
per patient-year 
61
. The risk of thrombo-embolism depends not only on prosthesis type but also on 






7.2.1. Descriptive data (Table 17) 
For the sample population, 146 patients (82.5%) had no documented adverse event. There were 31 
patients with at least one adverse event (17.5%) with ten patients (5.6%) sustaining multiple events 
and 45 documented adverse events (point prevalence of 25.4%). Stroke (undefined) accounted for 21 
of the events (46.7%) and haemorrhage or admission for toxicity the remaining 24 (53.3%) events. 
There were no documented cases of a thrombosed or obstructed prosthetic valve. 
The AF cohort had 19 patients (19.8%) with at least one documented adverse event, seven patients of 
which sustained multiple events (7.3%) as compared to the valve prosthesis cohortin which 12 
patients (14.8%) sustained at least one adverse event and three patients (3.7%) sustaining multiple 
adverse events. 
The AF cohort accounted for 28 (62.2%) of the 45 documented adverse events in the sample 
population (Figure 17), as compared to the valve prosthesis cohort which accounted for 17 (37.8%) 
documented events. The majority of the events in the AF cohort was stroke (undefined) which 
accounted for 18 (64.3%) of the events in the AF cohort compared to the valve prosthesis cohort 
which had three documented strokes (undefined) and accounted for 17.6% of the events in that cohort. 
The valve prosthesis cohort had 14(82.4%) haemorrhagic or toxic events as compared to the AF 






























at least one 
adverse 
event 
Adverse Event sustained 
Stroke Toxicity 













Mean age (years) 54.2  63.6 61.6 54.2 63.6 
Mean days between tests 33.6 30.4 31.9 34.2 29.3 
Mean time below range 48.3% 28.5% 39.9% 27.7% 49.4% 
Mean time above range 23.2% 22.3% 27.1% 29.4% 22.6% 
Mean time with INR > 4.00 10.2% 12.3% 14.9% 11.7% 16.7% 
Mean TTR 28.2% 49.2% 33.0% 42.9% 28.8% 
      











 3 (30%) 
7 (70%) 
Mean age 
 Less than 65 years 
 65-<75 years 





















Mean days between tests 31.5 31 29.1 30 27.3 
Mean time below range 31.2% 17.6% 21.9% 15.6%* 32.4% 
Mean time above range 27.5% 19.7% 31.9% 32.7% 24.6% 
Mean time with INR > 4.00 8.1% 6.6% 13.4% 10.9% 15.1% 
Mean TTR 40.8% 56.0% 46.1% 51.6% 42.9% 
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Mean days between tests 35.9 29 36.3 52 31.1 
Mean time below range 67.5% 53.8% 68.5% 80.1% 64.6% 
Mean time above range 18.5% 28.2% 19.3% 14.9% 20.8% 
Mean time with INR > 4.00 12.6% 25.7% 17.3% 14.9% 18.1% 
Mean TTR 14.1% 17.9% 12.2% 4.9% 14.6% 
Target INR : 2.5-3.0 14 (20.3%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Target INR: 3.0-3.5 16 (23.2%) 1 (33.3%) 5 (41.7%) 0 (0%) 6 (42.9%) 
Target INR: 3.5-4.0 39 (56.5%) 2 (66.7%) 7 (58.3%) 3 (100%) 8 (57.1%) 
*- p<.05 when compared to patients with haemorrhage or toxicity**-p =.004 when compared to patients who 




Figure 17: Distribution of adverse events between the AF cohort






























































































































7.2.2. Multiple events versus single events(Table 17) 
Interestingly, patients in our study population with more than one adverse event had spent 
significantly [t(29) = -2.685, p-.012] more time in the therapeutic range (M=49.2; SD=26.9) than 
patients who sustained only one adverse event (M=25.2; SD=21.3), albeit overall with a suboptimal 
TTR. In addition, this subset of patients had a higher mean age (M=63.6 years; SD=16.3 versus 
M=60.7 years; SD=12.6), however this difference was not statistically significant [t (29) = -.550, p-
.586]. Patients with a single adverse event spent more time below range (M=45.4; SD=29.3), above 
range (M=29.3; SD=19.3) and with INR values greater than 4.00 (M= 16.2; SD=14.7) than patients 
with multiple events. (M=28.5; SD=21.1, M=22.3; SD=11.1 and M=12.3; SD=13.7 respectively). The 
difference for these conditions was not statistically significant [t (29) = 1.627, p-.115; t (27.667) = 
1.283; p-.210 and t (29) =.698, p-.490 respectively]. In addition, patients with a single adverse event 
were monitored less frequently (M= 32.7 days between tests; SD=17.0) than patients with multiple 






7.2.3. Adverse events in the AF subgroup 
7.2.3.1. Adverse event versus no adverse event 
In the AF cohort (Table 17), the mean age in years for patients who sustained at least one documented 
(M=66.6; SD=11.1) was higher than those who did not (M=64.2; SD=11.3), however, this difference 
was not statistically significant [F (1, 94) =.702, p-.404]nor for any of the different age groups [F (1, 
94) = 1.460, p -. 230]. 
There was no statistically significant gender difference between patients who sustained an adverse 
event compared to those who did not [F (1, 94) =3.691, p-.058]. 
Patients who sustained an adverse event were monitored more frequently (M=29.1 days apart; 
SD=5.0) as compared to those who did not have an event adverse event (M=31.5 days apart; SD= 
7.1). This difference was not significant [F (1, 94) = 1.895, p-.172]. 
The difference in the mean percentage time below range was not significant between the group of 
patients who did not have at least one adverse event (M=31.0; SD=20.2) and those who did (M=21.9; 
SD=16.9) [F (1, 94) = 3.267, p-.074]. Patients who did not sustain at least one adverse event had a 
lower mean percentage time than those who did for the conditions of time above range (M=27.5; SD= 
17.0 and M=31.9; SD=18.1), time with INR values greater than 4.00 (M=8.1; SD=9.8 and M=13.4; 
SD=14.4) and TTR using the Direct method (M=40.8; SD=18.8 and M=46.1; SD=22.9) respectively. 
Statistically, these differences were not significant for any of the conditions [F (1, 94) = 1.022, p-
.074], [F (1, 94) = 3.716, p-.057] and [F (1, 94) = 1.117, p-.293] respectively. 
7.2.3.2. Stroke versus haemorrhage. 
In the AF cohort, we compared the population who sustained any stroke (undefined) with the 
population that sustained any haemorrhage or admission for toxicity (Table 15). There was a 
significant difference in the mean percentage time below range [t (19) =-2.632, p-.016] and for age [t 
(19) = -2.277, p-.035] between the groups. Patients sustaining a stroke spent less mean percentage 
time below range (M= 15.6; SD=12.8) than those with haemorrhage or toxicity (M= 32.4; SD=16.4) 
and the mean age of patients was significantly higher for patients with haemorrhage or toxicity 
(M=74.4 years; SD=6.7) than those with stroke (M=63.7 years; SD=11.9). Patients who sustained a 
stroke spent more time above range (M=32.7; SD=18.4), in therapeutic range using the Direct method 
(M=51.6; SD=20.9) and had less frequent monitoring (M=30.0 days apart; SD=4.7) than those who 
sustained haemorrhagic or toxic events (M=24.6; SD=19.1; M=42.9;SD=26.4 and M=27.3 days apart; 
SD=4.7 respectively), although these differences were not statistically significant[ t(19) =.974, p-.342; 
t(19) =.835, p-.414 and t (19) =1.262, p-.222 respectively].Patients with haemorrhage or toxicity 
(M=15.1; SD=18.1) had higher mean percentage time with an INR value greater than 4.00 compared 
to the group with stroke (M=10.9; SD=11.3), though the difference was not significant [t (19) = -.657, 
p -.519]. 
In patients with AF, a Poisson regression using Wald chi-square test for significance was run to 
predict the effects of gender, age, days between INR tests, time below range, time above range, time 
with an INR value greater than 4.00 and TTR on sustaining and adverse event. We found that the only 
condition which had statisticalsignificance as a predictor was the time with an INR value greater than 
4.00, p-.035. For every extra percentage time with an INR value greater than 4.00, there would be 




7.2.4. Valve prosthesis cohort: 
7.2.4.1. Adverse event versus no adverse event. 
In the valve prosthesis cohort (n=81), the only significant difference [F (1, 79) = 8.799, p-.004] 
between patients who sustained an adverse event (M=53.7; SD=14.1) and those who did not (M=39.8; 
SD=15.1) was for the condition of age in years. There was no significant difference for gender [F (1, 
79) =.772, p-.382] nor for the condition of target INR range [F (1, 79) =.842, p-.362] between the two 
groups (Table 17). 
Patients in the valve prosthesis cohort, who sustained an adverse event spent a higher percentage time 
below range (M=68.5; SD13.7), above range (M=19.3; SD=12.9) and time with an INR value greater 
than 4.00 (M=17.3; SD=14.3) and had less frequent monitoring (M=36.3 days apart; SD=21.5) than 
those with no documented event (M=67.6; SD=21; M=18.5;SD=14.1; M= 12.6; SD=10.2; M=35.9 
days apart; SD=14.8 respectively). These differences were not significant across these conditions [F 
(1, 79) =.021, p-.886; F (1, 79) =.038, p=.846; F (1, 79) = 1.881, p -.174 and F (1, 79) =.007, p-.933 
respectively]. 
Patients who sustained an event in the valve prosthesis cohort spent less time in the therapeutic range 
(M=12.2; SD=12.1) than those who did not (M=14.1; SD=12.9), however the difference was not 
statistically significant [F (1, 79) =.226, p-.636]. 
 
7.2.4.2. Stroke versus haemorrhage. 
We then compared patient subsets in the valve prosthesis sub-cohort who sustained a stroke and those 
with haemorrhage or toxicity (Table 17). 
Patients with haemorrhage or admission for toxicity spent more time above range (M=20.8; 
SD=14.3), with INR values greater than 4.00 (M=18.1; SD=16.2), in therapeutic range using the 
Direct method(M= 14.6; SD=13.1) than those who sustained a stroke (M=14.9; SD=7.9; M=14.9; 
SD=7.9 and M=4.9; SD-4.3 respectively). This difference, however, was not statistically significant [t 
(10) = -.673, p-.516; t (10) = -.327, p-.751 and t (9.875) = -1.917, p- 0.085 respectively]. In addition, 
patients with haemorrhage or admission for toxicity had INR monitoring performed more frequently 
(M=31.1 days apart; SD=6.6) and had a higher mean age(M=54.1; SD=15.5) than patients with a 
stroke (M=52.0; SD=43.3 and M=52.3; SD=11.2 respectively), although, the difference was also not 
significant. [T (10) =1.547, p-.153 and t (10) = -.181, p-.860 respectively]. 
Patients with the lowest target INR range (2.5 to 3.0) did not sustain any adverse event and all events 
categorised as stroke occurred only in patients with the highest target INR range (3.5 to 4.0). 
Haemorrhage or toxicity was documented for five patients with a target INR range of 3.0 to 3.5 and 4 
patients with a target INR range of 3.5 to 4.0. 
In patients with mechanical prosthesis valves, a Poisson regression using Wald chi-square test for 
significance was run to predict the effects of gender, age, days between INR testing, target INR ranges 
time below range, time above range, time with an INR value greater than 4.00 and TTR on sustaining 
and adverse event. We found that the conditions which had a strong statistical significance as a 
predictor were the time below range (p<.001) and the time above range (p<0.001). For every extra 




adverse events and for every extra percentage time spent above range patients with valve prosthesis 
would sustain 8.458 (95% CI, 7.267 to 9.843) times the number of adverse events. 
 
7.3. Discussion 
The prevalence of adverse events in our patient population is worrying. Thirty-one of the 177 patients 
studied sustained at least one adverse event (17.5%) with ten patients (5.6%) sustaining multiple 
events. There were 45 documented adverse events with a point prevalence of 25.4% or 1 in 4 patients 
sustaining an adverse event. The majority of documented adverse events were accounted for by 
patients with AF (62.2% of events), of which the majority being stroke which accounted for 64.3% of 
all events and 18 (85.7%) of all strokes sustained. Unfortunately, our study design, did not allow for 
interpretation of incidence rate or rate per annum or in person-years. However, in comparison to other 
studies that have described frequency of events, the patients in our population demonstrated much 
worse prevalence of complications. In the AF cohort, the prevalence of bleeding events was 10.75% 
and that of thrombotic events was 18.75%. In the AuriculA trial, which assessed 4273 patients in two 
centres for anticoagulation control in Sweden, the frequency of bleeding events was 2.03% and 1.36% 
for thrombosis for the whole study population. The AF subgroup (n=2491) in that study demonstrated 
53 (2.13% of AF subgroup) cases of bleeding and 1.16% of the total AF subgroup accounted for 
thrombotic events. The subgroup with heart valve dysfunction demonstrated 2.01% of bleeding and 
2.35% of thrombosis
49
. The subgroup of patients with prosthetic valves in our study showed 14 
bleeding events accounting for 17.28% of this subgroup and three stroke events (3.7%). Connolly et 
al., evaluated a regional influence using data from the ACTIVE-W trial. That study had 98 South 
African participants, none of which were in the upper two quartiles of TTR (mean TTR=46.3%) and 
there were eight documented events (8.1%)
34
. Sonuga, B.O et al., studied 136 patients attending an 
anticoagulation clinic in Cape Town, South Africa, of which 19 patients (14%) had bleeding events 
and three patients (2.2%) had thrombotic events
62
. While the high prevalence of adverse events in our 
study is closer to other South African samples, there are some differences between the studies. The 
participants in AuriculA demonstrated a much higher TTR (mean of 74.9%) than our patients. The AF 
cohort in AuriculA was not exclusively comprised of non-valvular AF and the patients in their valve 
disease subgroup included participants beyond those with mechanical prosthetic valves. The 
ACTIVE-W included myocardial infarction and death in their count of events. The study by Sonuga, 
B.O et al., was conducted on patients exclusively from a specialised anticoagulation clinic. 
Patients with AF in our study demonstrated more adverse events than patients with prosthetic heart 
valves. The most likely association with this finding is the difference in age. The meta-analysis by 
Bloomfield found older age to be consistently associated with haemorrhage
39
. Indeed, the CHA2DS2-
Vasc score (Table 2) considers an age above 65 years as a major risk factor for stroke in patients with 
AF as does the HASBLED bleeding risk tool for the risk of haemorrhage. While the mean age of 
patients with stroke in the AF subgroup was comparable with those who did not have an event (63.7 
years vs. 64.2 years), patients in this subgroup with haemorrhage demonstrated a mean age of 74.4 
years. Similarly, patients in the valve prosthesis subgroup who did not sustain an event had a mean 
age less than 40 years whereas those who did had mean ages beyond 50 years. In the AF subgroup we 
further demonstrated a significant association of older age and haemorrhage. This is consistent with 







In the AF cohort we evaluated for differences between patients with multiple events and single events. 
Those with multiple events had superior TTR than those with single events and this is likely the effect 
of sustaining multiple events when both the patient and the clinician likely employed more stringent 
control. This is supported by the finding of more frequent monitoring in this category of patient. 
Furthermore, patients with multiple events demonstrated a higher mean age than those who had a 
single event, although this difference was not significant. 
In the valve prosthesis cohort, we again demonstrated an older age to be a significant factor in 
sustaining an adverse event. Furthermore, we showed the time out of range was an important predictor 
for an adverse event. This is consistent with various studies emphasising the benefit of high TTR in 
reducing the risk of adverse events. 
Interestingly, despite the majority of patients in the valve prosthesis subgroup having suboptimal 
anticoagulation as demonstrated by the high percentage time below range, there were no documented 
events of valve thrombosis. The most likely reason is that valve thrombosis is rare and patients most 
susceptible to this event are those within the first six months of implantation. In our study, we 
evaluated patients on warfarin for at least one year and therefore the findings may not be 
representative of such patients. Furthermore, given the devastating effect of valve thrombosis and 
high risk of mortality, we may not have included these patients as we enrolled participants on their 
attendance and would therefore not have included possible mortality cases. 
Our study had various limitations in assessing adverse events. Firstly, the documentation of the event 
was reliant on good note-keeping by the clinician. Secondly, we evaluated only outpatient charts and 
events requiring admission may have not been stated. Further, we could not differentiate between 
ischaemic stroke and haemorrhagic stroke, mainly because patients in this study setting do not have 
easy access to neuro-imaging and the majority of these patients did not have a computed tomography 
or magnetic resonance imaging of the brain. In addition, because we did not evaluate inpatient folders, 
we could not strictly adhere to the ISTH guidelines when defining major bleeding and as a result may 
have overstated haemorrhagic events. Nonetheless, our evaluation of adverse events in this population 
is in line with the findings that older age confers greater risk of events especially bleeding, time above 
range and with an INR greater than 4.00 increases the risk of bleeding and time below range that of 






GENERAL DISCUSSION AND CONCLUSION 
 
8.1. General discussion 
We report the results of a single centre, community-based study of patients being anticoagulated for 
non-valvularAF and mechanical prosthetic heart valves in the setting of usual care and not a 
specialised anticoagulation clinic. We demonstrated a high variability in quality of anticoagulation 
among these patients and identified contributing factors. Further, we evaluated the impact of such 
quality by assessing the adverse outcomes in this population, which is the most important clinical 
implication. 
Interestingly the gender representation in our study population of patients with AF contrasted to 
reported global epidemiology. The Global Burden of Disease study which evaluated the epidemiology 
of AF, reported a higher male predominance globally, in developed and developing regions
3
. Females 
in our population constituted almost twice as many as males (65.6% vs. 34.4%). However the female 
representation in our study was similar to two South African (both are Cape Town based) studies 
evaluating patients on warfarin
53,62
. These findings suggest that in South Africa, females constitute at 
least a higher prevalence of AF than in developed regions, the clinical implications of which are 




8.2. Summary of the main results 
8.2.1. Variation in TTR. 
Overall, the patients in our study demonstrated poor quality of anticoagulation regardless of the 
indication. The mean TTR achieved in patients with AF was 44.5% which is considerably lower than 
the recommended minimum of 60%. Most studies conducted in developed regions have reported a 
superior TTR
34,38,39,46-49,51
. We do note that the findings in our study are closer to the findings of other 
African studies and the South African participants in global studies
34,42,46,62
.We demonstrated a highly 
significant difference in TTR by indication. Patients with AF achieved significantly higher (p <.001) 
TTR than those with prosthetic mechanical valves, albeit with both subgroups demonstrating low 
TTR. Patients with prosthetic heart valves demonstrated a mean TTR of 13.7%. 
8.2.2. Variation in quality of anticoagulation by indication 
The highest percentage time out of range was below range for both subgroups but this was more 
significant (p<.001) in patients with prosthetic valves (67.7% of the time was below range) than 
patients treated for AF. This was a consistent findings across all conditions namely time above range 
(p<.001), time with an INR greater than 4.00 (p<.05) and indeed TTR (p<.001). Although there are 
few studies comparing TTR across indications, it is reasonable to assume that patients with prosthetic 
valves are badly anticoagulated in this study population. Wielochetal., in the AuriculA study 
demonstrated a higher TTR in the subgroup of patients with mechanical valves than those with AF
49
. 
There are various factors that may account for this disparity in anticoagulation quality between the 




prosthetic valves, females had a higher percentage representation in the valve prosthesis subgroup and 
patients with prosthetic valves had a higher INR target. All these factors have been validated as 
contributors to poor anticoagulation 
31
. 
8.2.3. Gender association with quality of anticoagulation 
A few studies have consistently associated female gender with poorer anticoagulation quality 
9,31,48
. 
The findings in our study were inconsistent with these and there was no gender association with poor 
anticoagulation quality demonstrated. This is likely because unlike the global representation of male 
preponderance in AF, females represented the majority of the patients in our population
3
. Further, we 
showed males actually had poorer quality of anticoagulation with the time spent under-anticoagulated 
significant. It has been reported that in South Africa, males tend to seek health care less often than 
females and this trend could indeed account for this finding. 
8.2.4. Age association with quality of anticoagulation 
We demonstrated no statistically significant difference between age categories for both the AF 
subgroup and the valve prosthesis subgroup. In the AF subgroup, the TTR determined by the 
Rosendaal method in our study showed the best TTR was in patients younger than 65 years old which 
contrasted with the findings from other studies which reported better TTR in older patients 
38,48
. This 
finding is likely a result of the overall poor TTR across all age groups in our population. Nevertheless, 
the findings in our study imply a high risk of poor anticoagulation and therefore adverse events even 
if the patient is younger than 65 years old. It is noteworthy that patients in the AF group who were 
older than 65 years (which confers a higher risk for haemorrhage according to the HASBLED score) 
spent more time with an INR value higher than 4.00 which is additive in risk for bleeding. This trend 
was consistent in the subgroup of patients with prosthetic valves, where those older than 60 years old 
had the highest mean proportion of time with INR values exceeding 4.00. This is likely due to the 
altered pharmacodynamics, altered enzymatic activity and concomitant drug use in the elderly but this 
needs formal validation. 
8.2.5. Association of frequency of INR testing and quality of anticoagulation 
In patients with AF there was no association that was statistically significant with frequency of INR 
testing. In patients with prosthetic valves, the time spent below range was significantly higher (p-.023) 
if INR testing was performed less frequently. Given that patients are prescribed warfarin for a 
maximum of 28 days before prescription renewal in this setting, it is likely that there is a period for 
which there is no anticoagulant being taken and this is probably an influential factor for low INR 
values. This finding was consistent in the AF subgroup but not statistically significant. In line with 
this explanation, patients monitored more frequently demonstrated more time above range if tested 
less than 28 days apart than those tested less frequently, however this was only significant in the valve 
prosthesis cohort (p-.035) for patients tested between 28 to 32 days apart and those tested more than 
32 days apart. In keeping with the association of more time above range with frequent testing, patients 
in the valve prosthesis subgroup showed significantly more time with an INR value higher than 4.00 if 
tested less than 28 days apart than those with test intervals more than 32 days (p-.016). 
Patients monitored between 28 and 32 days apart demonstrated the best TTR for both indications. 
This was significant in the valve prosthesis cohort for patients tested 28 to 32 days apart and those 
with test intervals more than 32 days when using the Rosendaal method. (p-.034). Some studies 
evaluating TTR favour more frequent testing 
37,38






8.2.6. Association of target INR range and quality of anticoagulation 
The lowest target INR range in our study was entirely constituted by the patients treated for AF and 
was from 2.0 to 3.0. Patients with this target INR range had the best quality of anticoagulation and 
significantly better TTR, the least time below and the lowest risk of bleeding by having the lowest 
percentage of time with INR values in excess of 4.00 (p<.05). Within the valve prosthesis subgroup, 
patients with the lowest target INR range (2.5 to 3.0) demonstrated significantly better TTR, less time 
below range and above range when compared to the subgroup of patients with the highest target INR 
range (3.5-4.0) (p<.05). These patients also had the lowest proportion of time with INR more than 
4.00 within the valve prosthesis cohort but this was not statistically significant (p-.112). However, the 
patients with target ranges from 2.0 to 3.0 and from 2.5 to 3.0 both had significantly higher 
proportions of time above range. Despite this, they still demonstrated the lowest times with an INR 
exceeding 4.00 and maintained a lower bleeding risk than those with higher target ranges. 
8.2.7. Adverse events 
Overall, the findings in our study demonstrated poor quality of anticoagulation and therefore suggest  
that the patients in this study are at higher risks of adverse events and indeed we evaluated a point 
prevalence of 25.4% across the entire cohort and 17.5% of the patients studied had sustained at least 




The majority of strokes sustained were accounted for by patients with AF (85.7%) while the majority 
of haemorrhagic events were accounted for by patients from the prosthetic valve subgroup (58.3%). 
We also demonstrated that the time with an INR above 4.00 is a significant risk factor for an adverse 
event. In our study sample, there was a highly significant poorer TTR in patients with prosthetic 
valves compared to those with AF (p<.001). Further, patients with mechanical valve prostheses spent 
a much higher time below range (p>.001) than those with AF and even though they had much less 
time above range (p<.001) they recorded higher proportions with INR exceeding 4.00 (p<.05). These 
findings allow us to draw the conclusion that poor TTR is associated with high risk of bleeding and 
while the time above remains noteworthy, it is the time with INR values exceeding 4.00 that have 
been shown to significantly be associated with haemorrhagic risk. 
 
8.3. Study Limitations 
The main limitation of this study was that it was retrospective and single centre based and as a result 
may not be entirely representative for a region. It is, however, to the best of our knowledge the first 
study evaluating the quality of anticoagulation in a community-based setting for both AF and 
prosthetic heart valves in KwaZulu Natal. 
Only outpatient folders were analysed and therefore INR values registered in inpatient files or at other 
facilities may not be represented. The patient population was derived from record keeping of INR 
sampling and therefore only live cases were analysed. As a result, we were unable to evaluate for 
associated mortality which remains the most important clinically relevant outcome. Nonetheless, we 
believe this method of sample recruitment remains the best to achieve the most real-life representation 




Furthermore, adverse events were entirely reliant on the documentation of such by the attending 
clinician in the outpatient folder and this may have resulted in under-representation of events. The 
most important limitations in evaluating events however, was the lack of documented neuro-imaging 
findings and we were therefore unable to define any stroke as ischaemic or haemorrhagic and the 
study design precluded us from accurately evaluating for haemorrhage as defined by ISTH guidelines 
59
 and this may have over-represented the number of bleeding events. 
Finally, the data did not include some factors that are known to affect TTR like patient education 
regarding warfarin use, patient compliance, socio-economic conditions, ethnicity, tobacco use, alcohol 
use, warfarin resistance and lastly although age was used as factor conferring high risk in AF, a 





Non-valvular AF and prosthetic heart valves account for the majority of indications (75.3%) for which 
patients are being anticoagulated at this study location. 
This study confirms poor quality of anticoagulation in this patient population across both indications 
for anticoagulation namely non-valvular AF and valve prosthesis with the latter subgroup 
demonstrating poorer quality. The study demonstrates a major gap in quality of anticoagulation 
compared to developed regions and indeed confirms that the majority of patients (76%) are not 
achieving the recommended minimum TTR of 60%. 
This study confirms that the fraction of INRs is a reasonable method for evaluating TTR and 
correlates well with the Rosendaal method. 
We found no gender or age association with TTR, however INR testing intervals less than 32 days 
apart and lower target ranges were significant factors favouring better anticoagulation quality. 
The majority of time out of range was below target range and this predisposed these patients to 
thrombo-embolic complications. Patients in this study spent a substantial proportion of time with an 
INR exceeding 4.0 and this conferred higher risk to haemorrhagic complications. Indeed, a high 
prevalence of adverse events was demonstrated and older age and proportion of time out of range was 
a significant factor in sustaining an event. 
The findings in this study have remarkable clinical implications. Firstly, further research is required to 
determine the factors contributing to poor anticoagulation in this population and then proposals based 
on these findings need to be agreed upon and instituted. These findings also suggest that presently, 
patients with AF and prosthetic valves are not benefiting from OAC therapy and indeed are at high 
risk for events. This is important for all stakeholders in health care decision-making to determine if 
patients in this subpopulation may show improvement if treated in a specialised anticoagulation clinic 
where an algorithmic approach is utilised or perhaps consider implementing point-of-care devices, 
adjust frequency of visits or indeed even benefit more from a NOAC than to continue with current 
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Title of the Study: 
Warfarin: Time in Therapeutic Range(TTR), A single centre retrospective study on patients using 
Warfarin for stroke prevention in non-valvular Atrial Fibrillation(AF) or for patients with Prosthetic heart 
valves. 
 
Aim of the study: 
To assess the quality of anticoagulation of patients on warfarin for stroke prevention in non-valvular 
Atrial Fibrillation or in the presence of prosthetic heart valves. 
 
Specific Objectives: 
1. To assess the Time in Therapeutic Range (TTR) of patients on Warfarin for stroke prevention in 
non-valvular Atrial Fibrillation or in the presence of prosthetic heart valves. 
2. To assess the indication for anticoagulation namely for stroke prevention in Atrial Fibrillation or if in 
the presence of prosthetic heart valves. 
3. To assess the frequency of suboptimal INR levels or toxic levels of INR in relation to Time in 
Therapeutic Range 
4. To assess for any gender association with TTR of patients on Warfarin. 
5. To compare findings of the TTR using three different methods. 
 
Background and Literature: 
Vitamin K Antagonists (VKA) such as Warfarin are widely prescribed as oral anticoagulants. The 
efficiency of anticoagulation with Warfarin is measured by the prothrombin time reported as an 
International Normalisation Ratio (INR) with a different target range for the individual disease 
condition.  
This is done by measuring the Prothrombin Time (PT), International Normalized Ratio (INR), which is 
a measure of three of the four vitamin K–dependent coagulation factors: II, VII and X. The INR is 
determined by dividing the PT of a patient with the geometric mean of PT for at least 20 healthy 
subjects of both sexes with the same test system. An INR of 1.0 is considered to be normal 
coagulation and an INR of 2.0 means that the clotting time has been doubled [1]. 
VKA produce their anticoagulant effect by interfering with the cyclic interconversion of vitamin K and 
its epoxide which through a complex pathway leads to the depletion of coagulant proteins 
(prothrombin, factor VII, factor IX, and factor X). In addition, the VKA impair the regulation of the 
anticoagulant proteins (protein C and protein S) and impair their function [1]. 
Warfarin as an anticoagulant agent has many uses. The two notable indications for long-term oral 
anticoagulation are in the setting of non– valvular Atrial Fibrillation to prevent stroke and/or systemic 




risk of morbidity and mortality because of a substantially increased risk of stroke and systemic 
thrombo-embolism. Overall, AF increases the stroke risk 5-fold, and when compared with non-
AFrelated strokes, strokes related to AF are associated with higher mortality, greater disability, longer 
hospital stays, poorer functional outcome, and lower chance of being discharged home[2]. The 
Framingham study has noted AF as an independent risk factor for stroke [3]. 
The risk of stroke in AF is reduced by antithrombotic therapy. Thromboprophylaxis can be obtained 
with VKA like Warfarin or a non-VKA oral anticoagulant. All the major guidelines emphasize the role of 
oral anticoagulation (OAC) use for stroke prevention in AF[2, 4, 5]. 
The introduction of valve replacement surgery in the early 1960s has dramatically improved the 
outcome of patients with valvular heart disease. 
Patients with prosthetic valves are at risk of thrombo-embolic complications, including systemic 
embolization, most commonly cerebral and prosthetic thrombosis causing valve obstruction and/or 
regurgitation. The risk of thrombo-embolic events is higher with mechanical than with bioprosthetic 
valves, higher with mitral than with aortic prosthetic valves, and higher in the early (3 months) versus 
late postoperative phase [6]. The risk  is also increased in the presence of concomitant risk factors for 
thrombo-embolism, including atrial fibrillation, Left Ventricular (LV) dysfunction, left atrial dilation, 
previous thrombo-embolism, and a hypercoagulable condition. 
Patients with mechanical prostheses require lifelong anticoagulation with Warfarin and for 3 months in 
the case of an implanted bioprosthesis. Lifelong anticoagulation is required in the case of a 
bioprosthesis implantation if the patient has other indications for anticoagulation [7]. 
INR target ranges vary per country and per indication. The most common usual target INR is in the 
range 2-3[1]. The optimal range is generally determined by defining the risk of thrombo-embolism 
against the risk for haemorrhage. 
Patients with AF who require Warfarin for the prevention of cardio-embolic complication should have 
an INR target of 2.5[8]. 
The recommended INR targets for mechanical heart valves depends on the prosthesis 
thrombogenicity (Low: Carbomedics (aortic position), Medtronic Hall, St Jude Medical (without 
silzone); Medium: Bjork-Shiley, other bi-leaflet valves; High: Starr-Edwards, Omniscience, Lillehei-
Kaster) as well as patient factors which increase the risk of thrombo-embolism (Mitral, tricuspid or 
pulmonary position; Previous arterial thrombo-embolism; AF; Left atrium diameter >50 mm; Mitral 
stenosis of any degree; Left ventricular ejection fraction <35%; Left atrial dense spontaneous echo 
contrast). 
Patients with low prosthetic thrombogenicity and no patient risk factors should have an INR target of 
2.5. Those with low prosthesis thrombogenicity and patient risk factors should be optimised at an INR 
of 3.0. Patients with Medium prosthesis thrombogenicity and no patient risk factors have an INR 
target of 3.0 whereas those with patient risk factors should have INR levels at 3.5. In patients with 
high prosthesis thrombogenicity, regardless of patient risk factors, an INR of 3.5 should be targeted 
with some studies suggesting an INR of 4.0 to be considered [8]. 
The clinical benefits and risks of Warfarin are associated with the proportion of time that INR values 
are within the target range, meaning the Time in Therapeutic Range (TTR).The quality of 
anticoagulation control is well accepted as an indicator in many clinical trials, however, it is often not 
measured. The TTR is a good indicator for the quality of anticoagulation control. 
There are at least three different methods to measure TTR: 1.Fraction of INRs in range (taken as the 
number of INRs in range divided by the total number of INRs for the study interval); 2.The cross-
section-of-the-files-methodology (takes each patient whose INR is in range at one point in time 




Interpolation Methodology (uses a computer software program called the INR-DAY programme that 
assumes a linear relationship exists between two INR values and allows one to calculate a specific 
INR value to each day for each patient) [9]. 
TTR is an important and validated quality measure for VKA management [10]. Patients who are 
under-treated remain at risk of thrombo-embolic events and patients who receive too much 
anticoagulant therapy are exposed to unnecessary bleeding risk.[11] 
In the setting of non-valvular AF, patients who have at least one other stroke risk factor are 
recommended to receive effective stroke prevention therapy, which is essentially an OAC with either 
well-controlled VKA therapy (INR 2–3, with a high TTR percentage of, at least 70%) or one of the 
Novel Oral Anticoagulants (NOAC)[5]. 
There is a strong correlation between TTR and survival of post AF stroke for moderate or high risk 
patient under Warfarin treatment, with a much better survival for the patient with TTR >70 % 
compared to patients at lower TTR. In terms of quality, the “Quality of TTR” was presented as < 50 
%= bad quality, > 65 %= best practice in Randomised Controlled Trials, > 80 % = optimal[12].The 
report from the ACTIVE-W trial indicated that if the TTR was below 65%, the benefit of Warfarin 
therapy over aspirin was lost[13, 14]. 
In the case of non-valvular AF, major bleeding incidence increased with increasing INR. Major 
bleeding event rates per patient-year were 1.7 for INRs <1.49, 1.8 for INRs between 1.50–1.99, 1.5 
for INRs between 2.00–2.49, 3.4 for INRs between 2.50–2.99 and 20.0 for INRs >3.00 [15]. 
A high variability of the INR is the strongest independent predictor of reduced survival after 
mechanical valve replacement. Valve thrombosis is most often encountered in patients with 
mechanical valves and inadequate antithrombotic therapy [6]. 
A correlation between treatment quality with Warfarin as measured by TTR and serious 
complications, mainly bleeding but also death has been shown. In order to have the lowest possible 
risk of complications, the aim of Warfarin therapy in patients with mechanical heart valve prosthesis 
should therefore be to keep the patient’s TTR within the top quartile, i.e. TTR > 83% [16]. It is 
plausible that TTR of 70% is already sufficient for prevention of valve thrombosis [16]. 
The high variability in INR and therefore in TTR poses a difficult challenge to the clinician. The 
pharmacokinetics, pharmacodynamics and pharmacogenetics of warfarin contribute a major role 
toward this variability. Warfarin has multiple dietary interactions as well as multiple drug interactions 
[17]. 
Vitamin K is the natural antidote to Warfarin. Vitamin K is found in food, and diet therefore imposes 
variability in Warfarin response. Normal intake of vitamin K is in the range of 60–200 µg/day. Most 
dark green vegetables such as broccoli, brussels sprouts and spinach contain high levels of vitamin K 
(>100 µg/2 dl), but also other common foodstuffs contain a fairly large amount of vitamin K. It is 
estimated that an increase in vitamin K intake of 100 µg per day for 4 consecutive days lowers the 
INR by 0.2, and Vitamin K intake has therefore been incorporated into some Warfarin dose prediction 
models [1]. 
The two Warfarin isomers are metabolised by different pathways. The main enzyme involved in the 
metabolic elimination of (S)-Warfarin is CYP2C9, while (R)-Warfarin is eliminated by 
CYP1A1/CYP1A2/CYP3A4.  Patients starting or stopping drugs that are known inducers or inhibitors 
of these enzymes should have extra INR tests, and their dose of Warfarin adjusted accordingly. 
Examples of drugs that interact with Warfarin are Amiodarone that inhibits the clearance of Warfarin 
thereby potentiating the anticoagulant effect, and carbamazepine, phenytoin and rifampicin, which 
induce the metabolism of Warfarin. Drugs that inhibit clotting and increase the risk of bleeding, like 
aspirin, Diclofenac and Ibuprofen, are also regarded as interacting drugs even though they have no 




In one study of patients with outofrange INRs, non-compliance was most commonly noted in 214 
occasions (19.8%), food in 143 occasions (13.2%), drugs in 109 occasions (10.0%), alcoholic 
beverage in 34 occasions (3.1%) and herbal remedy in 12 occasions (1.1%).The remaining 52.8% 
was undetermined [18]. 
   
References 
1. Eriksson, N. and M. Wadelius, Prediction of warfarin dose: why, when and 
how? Pharmacogenomics, 2012. 13(4): p. 429-440. 
2. Lip, G.Y. and D.A. Lane, Stroke prevention in atrial fibrillation: a systematic review. JAMA, 
2015. 313(19): p. 1950-62. 
3. Wolf, P.A., R.D. Abbott, and W.B. Kannel, Atrial fibrillation as an independent risk factor for stroke: 
the Framingham Study. Stroke, 1991. 22(8): p. 983-8. 
4. Rose, A.J., et al., Warfarin for atrial fibrillation in community-based practise. Journal of Thrombosis 
and Haemostasis, 2008. 6(10): p. 1647-1654. 
5. Camm, A.J., et al., 2012 focused update of the ESC Guidelines for the management of atrial 
fibrillation: an update of the 2010 ESC Guidelines for the management of   atrial fibrillation. Developed 
with the special contribution of the European Heart Rhythm Association. Eur Heart J, 2012. 33(21): p. 
2719-47. 
6. Pibarot, P. and J.G. Dumesnil, Prosthetic heart valves: selection of the optimal prosthesis and long-
term management. Circulation, 2009. 119(7): p. 1034-48. 
7. Stepinska,J., Valve Emergencies,Prosthetic Valve Thrombosis. ESC Congress 2010. 
8. Keeling, D., et al., Guidelines on oral anticoagulation with warfarin - fourth edition. Br J Haematol, 
2011. 154(3): p. 311-24. 
9. Schmitt, L., J. Speckman, and J. Ansell, Quality Assessment of Anticoagulation Dose Management: 
Comparative Evaluation of Measures of Time-in-Therapeutic Range. Journal of Thrombosis and 
Thrombolysis, 2003. 15(3): p. 213-216. 
10. Piccini, J.P., et al., Relationship between time in therapeutic range and comparative treatment 
effect of rivaroxaban and warfarin: results from the ROCKET AF trial. J Am Heart Assoc, 2014. 3(2): 
p. e000521. 
11. Apostolakis, S., et al., Factors affecting quality of anticoagulation control among patients with 
atrial fibrillation on warfarin: the SAMe-TT(2)R(2) score. Chest, 2013. 144(5): p. 1555-63. 
12. Larsen,T.B., Anticoagulation and patient cooperation go hand in hand.The journey to 70 % TTR – 
How do we get there? . 8th International Patient/Physician Conference                on Oral 
Anticoagulation Therapy, Vienna, Oct 4 th -6 th , 2012. 
13. Lader, E., et al., Warfarin therapeutic monitoring: is 70% time in the therapeutic range the best we 
can do? J Clin Pharm Ther, 2012. 37(4): p. 375-7. 
14. Connolly, S.J., et al., Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation 
depends on the quality of international normalized ratio control achieved by centers and countries as 




15.          Lopes,R.D., et al.,Stroke Prevention in Atrial Fibrillation.Comparative Effectiveness Review. 
AHRQ Publication No. 13-EHC113-EF August 2013. 
16.          Grzymala-Lubanski, B., et al., Mechanical heart valve prosthesis and warfarin - treatment 
quality and prognosis. Thromb Res, 2014. 133(5): p. 795-8. 
17. Hirsh, J., et al., Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal 
therapeutic range. Chest, 2001. 119(1_suppl): p. 8S-21S. 
18. Kim, J.H., et al., How well does the target INR level maintain in warfarin-treated patients with non-





Patients attending Mahatma Gandhi Memorial Hospital, Adult Medical Outpatients Department for 
assessment of non valvular Atrial fibrillation or valve prosthesis and treatment with Warfarin. 
Sampling strategy. 
Systematic Random sampling. 
Determined by the following method for each cohort. 
N = Total Number of patients in the study population (i.e: total number of patients meeting the 
inclusion criteria seen in the department during the period from 1
st
 October 2015 to 30
th
 November 
2015 for each cohort) 
n = sample size: 150 in the case of Atrial Fibrillation patients and 100 in the case of valve patients 
k = Interval size i.e. N/150 in the case of Atrial Fibrillation patients and N/100 in valve prosthesis 
A random number will be selected from 1-5 as a starting point and every “k”-th case will be accepted. 
The cases in the study population will be randomly ordered and not according to date of visit. 
Statistical Planning. 
Single centre retrospective observational study on patients attending Mahatma Gandhi Memorial 
Hospital – Adult Medical Outpatients Department during the period of 1
st
 October 2015 to 
30
th
 November 2015 for assessment of anticoagulation  while on Warfarin for either non-valvular Atrial 
Fibrillation, or in the presence of any valve prosthesis. 
The charts of these patients will be retrospectively reviewed for a period of 1 year or 12 visits 
whichever is the longer time period. 
Patients will be sub-categorised into cohorts of patients being anticoagulated for prevention of stroke 




The 2 cohorts will be further subdivided into age and gender as a means for comparison. 
Chart reviews will include age, gender, indication for anticoagulation, INR levels and the date of 
sampling, record of any event of haemorrhage or admission for Warfarin toxicity and record of any 
event of systemic thrombo-embolism while on anticoagulation not limited to the study period. 
In addition the chart review will include the average frequency of visits for assessment of 
anticoagualtion. This was included to assist in determining if the frequency of visits for INR sampling 
while on anticoagulation is influential in the outcome of TTR, and to consider it as a recommendation 
at the end. These will be subdivided between the AF cohort and the valve prosthesis cohort. 
All handwritten INR records will be confirmed via the National Health Laboratory Services (NHLS) 
Labtrack
R
 database using the patients’ demographics and the patient file number and/or the specimen 
tracking number. 
The indication for anticoagulation, presence or abscence of patient risk factors and/or any adverse 
event will be reliant on the documentation of the attending clinician. 
INR sampling in this centre is performed by sampling venous blood in a citrate tube. 
The target INR is determined by the recommendations made by Keeling, D., et al., Guidelines on oral 
anticoagulation with warfarin - fourth edition. Br J Haematol, 2011. 154(3): p. 311-24.This was opted 
for in view of the Laboratory Service in use, using the same recommended guideline in their reference 
to INR results. 
Therefore the adopted INR target range for patients in this study with AF will be 2.0-3.0. 
Patients with mechanical valve prosthesis will be subdivided as those with low, medium and high 
valve thrombogenicity in the presence or abscence of other risk factors according to the table below.  
Recommended INR Target 
Thrombogenicity No Risk Factors Risk Factors Present 
Low 2.5 3.0 
Medium 3.0 3.5 
High 3.5 3.5 
  
Time in Therapeutic Range will be determined by using the INR values viathree methods: 
1. The percent of visits in the range (this is the number of visits with INR in range divided by the total 
number of visits for the study period). 
2. The Rosendaal Linear Interpolation Methodology (use of a Microsoft Excel template downloaded 
from a website called Health Care Systems Solutions which assumes a linear relationship exists 
between two INR values and allows one to calculate a specific INR value to each day for each 
patient) 
3. Use of an Internet Downloaded software program from Formulae.com called Regulating 
Anticoagulant Treatment and abbreviated RATi. Input data include the indication for anticoagulation, 
the target INR, dates of INR results, and the weekly Warfarin dose. The program automatically 
calculates the percentage of the TTR. 




Interpretation of the results of the TTR in the cohort of patients with AF will include the following:  
1. The primary outcome is to determine the overall TTR. 
2. The percentage of patients with TTR <65%, which will be considered suboptimal and “time 
with increased thrombotic risk”(Lader, Martin et al. 2012). 
3. The percentage of patients with TTR <50%, which will be considered as a marker of bad 
quality of anticoagulation control as well as “time with increased thrombotic risk”(Larsen,T.B. 
2012). 
4. The percentage of patients with TTR >70% which will be considered as satisfactory. 
5. The percent of visits in the range will also be interpreted to include the time in range of 
increased risk of haemorrhage and accepted as an INR >4.0. 
For 2,3,4 and 5 above, the data will be further stratified according to age and gender. 
  
Interpretation of the TTR in the cohort of patients with valve prosthesis will include the following:  
1. The primary outcome is to determine the overall TTR. 
2. The percentage of patients with TTR >70%, which will be considered satisfactory(Grzymala-
Lubanski, Labaf et al. 2014). 
3. The percentage of patients with TTR > 83%, which will be considered ideal.(Grzymala-
Lubanski, Labaf et al. 2014). 
4. The percentage of patients with TTR <70%, which will be considered suboptimal. 
For  2,3 and 4 above, the data will be further stratified according to age and gender. 
Reliability:  
The nature of testing is consistent throughout i.e. INR values are determined by the same laboratory 
for all sampled patients. The target INR is also consistent for the Atrial Fibrillation cohort and is in line 
with the laboratory reference. In the cases of patients with valve prosthesis, the INR reference may 
differ, in view of the risk factors and thrombogenicity being different, however, the TTR and deviation 
from target INR will not be compromised, as each case will be interpreted according to that target 
INR. In the case of any subject having had 2 samplings for INR on the same day the average of the 
two will be used. 
All subjects in both cohorts will have at least 12 INR readings used for interpretation. 
The data for TTR will be determined by three different methods,two of which are well published and 
generally accepted. The third being the RATi software, is based on similar calculation concepts of 
other previously used software tools used in interpreting TTR. 
However, determinants like the indication for anticoagulation, patient risk factors and any adverse 
event (haemorrhage/Warfarin toxicity/obstructed valve/any systemic thrombo-embolism) is reliant on 
the documentation of the attending clinician. A full and thorough chart review will be performed in all 
instances. Should the indication for anticoagulation or patient risk factors in the case of valve 
prosthesis still not be determined, the data from that chart review will not be used. 
Validity:  
The INR measurement is a valid and accepted method of determining the state of anticoagulation. 
The TTR is determined by interpretation of the INR. The two of the three methods proposed 




of visits in the range (which reviews INR results over a longer interval), is minimised by reviewing the 
results over 1 year or 12 visits. It has been previously used showing acceptable predictive value. 
Bias is minimised by sampling the INR of patients with the same method and using the same 
laboratory service and the same reference ranges regardless of demographic data. The reference 
ranges are individualised for the patients on anticoagulation for stroke prevention in Atrial Fibrillation 
and those with prosthetic valves, however they remain as separate cohorts to each other. 
Confounding Factors: 
Concomitant use of other drugs that interact with Warfarin and therefore affect the INR. 
Variability: 
Variability in diet between the different patients which may alter Warfarin metabolism and therefore 
the INR.   
Sample Size: 
Patients who attended the Gandhi Memorial Hospital, Adult Medical Outpatients Department from 
1
st
October 2015 to 30
th
 November 2015 will be randomly selected. 
Two cohorts are proposed: 
1. 150 Patients with non-valvular Atrial Fibrillation and on oral anticoagulants 
2. 100 Patients with valve prosthesis and on oral anticoagulants  
 
Inclusion Criteria  
Patients attending the Mahatma Gandhi Memorial Hospital, Adult Medical Outpatients Department 
were considered to be enlisted. The sample was determined by retrospectively reviewing the patients’ 
charts of those who attended the unit from 1st October 2015 to30
th
November 2015. 
Only outpatient subjects were considered. 
Any patient over the age of 12 years is enlisted if that patient has non-valvular Atrial Fibrillation and is 
on Warfarin therapy for at least 1 year. 
Any patients with any valve prosthesis and who are anticoagulated with Warfarin for at least one year 
above the age of 12 years old. By inference patients with bioprosthesis were not included. 
Exclusion Criteria  
Patients under the age of 12 years old were not considered for this study. 
Patients with valvular Atrial fibrillation without a mechanical prosthesis were not considered. 
Any patient on anticoagulation for less than one year was not considered. 




Any patient on oral anticoagulation with an undetermined indication, or not for the purposes of this 
study eg. Venous Thrombo-embolism was not considered. 
Any patient with a valve prosthesis but has an undetermined target INR due to lack of documentation 
of patient factors.  
 
Data collection tools and methods 
Sample selection: Systematically randomised. 





November 2015 at Mahatma Gandhi Memorial Hospital, Adult Medical Outpatients 
Department. These will be randomised to numbers 1 to N. 
Sample Size n– 150 patients with non-valvular Atrial Fibrillation and 100 patients with valve 
prosthesis.  Selected using an interval size k as described in Methods of sampling. 
Chart Audits:Once the sample cohorts are determined (by indication for anticoagulation), 
retrospective chart reviews will be undertaken to determine the following parameters for each patient: 
1. Age 
2. Gender 
3. Patient Risk Factors (in the case of valve prosthesis) which is Mitral, tricuspid or pulmonary 
position; Previous arterial thrombo-embolism; Atrial fibrillation; Left atrium diameter >50 mm; 
Mitral stenosis of any degree; Left ventricular ejection fraction <35%; Left atrial dense 
spontaneous echo contrast 
4. Prosthetic valve Thrombogenicity ( in the case of valve prostheses patients) 
5. INR values for the previous 1 year or least 12 values whichever is the longer time period 
6. Number of visits in the period determined in 4. 
7. Date of INR values as corresponds with patient visits. 
8. Documented adverse event (any period while on anticoagulation) which includes any 
haemorrhage, any admission for Warfarin toxicity, any systemic embolism, any obstructed 
valve 
This data will then be collected and distributed in table format for each patient as illustrated below: 
Patients being anticoagulated for stroke prevention in non-valvular Atrial Fibrillation:See Figure 1. 
Patients being anticoagulated in the presence of valve prosthesis:See Figure 2. 
Data Analysis Techniques 
For Assessment of TTR, each patient will have an accompanying chart, including the following: 
1. Rosendal Method as adapted from Microsoft Excel (see Figure 3. for example). 
2. The percent of visits in the range (see Figure 4. for example) 
3. The printout of the spreadsheet from the RATi software program 
In addition the Percentage of Visits above the range, Below the Range and above an INR of 4.0 will 
be recorded.  (See Figure 5,Figure 6 and Figure 7 for example) 




Figure 1. Data Collection Tool in the case of a patient on Warfarin for Stroke prevention with Non-Valvular Atrial Fibrillation 
Patient Reference No.  ( Corresponds with the number randomly assigned as part of population group N) 
Indication for Anticoagulation: Stroke prevention in non-valvular AF Age: Number of completed years Gender: Male or Female 
Adverse events and date of event:  
1._____________________2.________________________3.____________________4.__________________ 
5.__________________________6._________________________7.___________________________ 
Target INR range: 2-3 













INR above 4.0? 
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Total INRs above 
4.0 







Figure 2. Data Collection Tool in the case of a patient on Warfarin for valve prosthesis 
Patient Reference No.  ( Corresponds with the number randomly assigned as part of population group N) 
Indication for Anticoagulation: Valve Prosthesis Age: Number of completed years Gender: Male or Female 









Target INR range: 
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Figure 3. Example of Excel spreadsheet with Rosendaal method. 
Test Date INR 
Days 
Since Last 











INR Diff Below 
Range 
Days within 
Range since Last 
Test 
% Days within 
Range since Last 
Test 
30/05/2006 2.3        In Range             
06/06/2006 3.3 7 1 In Range Above Calculate 0.3 0.7 0 4.9 70% 
13/06/2006 2.5 7 -0.8 Above In Range Calculate 0.3 0.5 0 4.4 63% 
20/06/2006 1.8 7 -0.7 In Range Below Calculate 0 0.5 0.2 5.0 71% 
27/06/2006 2.1 7 0.3 Below In Range Calculate 0 0.1 0.2 2.3 33% 
04/07/2006 1.5 7 -0.6 In Range Below Calculate 0 0.1 0.5 1.2 17% 
11/07/2006 1.5 7 0 Below Below Below 0 0 0 0.0 0% 
18/07/2006 1.8 7 0.3 Below Below Below 0 0 0.3 0.0 0% 
25/07/2006 3.9 7 2.1 Below Above Calculate 0.9 1 0.2 3.3 48% 
01/08/2006 3.7 7 -0.2 Above Above Above 0.2 0 0 0.0 0% 
08/08/2006 3.5 7 -0.2 Above Above Above 0.2 0 0 0.0 0% 
15/08/2006 1.7 7 -1.8 Above Below Calculate 0.5 1 0.3 3.9 56% 
22/08/2006 2.4 7 0.7 Below In Range Calculate 0 0.4 0.3 4.0 57% 
29/08/2006 2.5 7 0.1 In Range In Range In Range 0 0.1 0 7.0 100% 
05/09/2006 3.2 7 0.7 In Range Above Calculate 0.2 0.5 0 5.0 71% 
12/09/2006 3 7 -0.2 Above In Range Calculate 0.2 0 0 0.0 0% 
19/09/2006 2.3 7 -0.7 In Range In Range In Range 0 0.7 0 7.0 100% 
 
Low Range 2 




Days Within Range Eg.425.1 
Total Days Eg.701.0 




Percentage in Range (Figure.4) 
Total Number of Tests 100.0 
Number of Tests in Range 51.0 





Percentage above Range (Figure.5) 
Total Number of Tests 100.0 
Number of Tests in Range 14.0 




Percentage below Range (Figure.6) 
Total Number of Tests 100.0 
Number of Tests in Range 21.0 





Percentage above INR  >4.   
(Figure. 7) 
 Total Number of Tests 100.0 
Number of Tests in Range 11.0 












Direct interpretation of the results as a percentage for the following categories for each cohort using 
the three methods described above: 
1. Percentage of time of INR within the therapeutic range 
2. Percentage of time of INR within the subtherapeutic range 
3. Percentage of time of INR within toxic range. 
Arithmetic Mean and Median will be used to characterise the poulation and directly interpret the 
findings as a percentage using the 3 methods discussed above. 
Standard Deviation will be used to disperse the data 
One way ANOVA will be used to evaluate differences across the indications. 
This study is predominantly observational and descriptive. Data will be analysed and a p-value <0.05 
will be considered significant. 
 
Study Location: 
Patients attending Mahatma Gandhi Memorial Hospital, Adult Medical Outpatients Department 
(Phoenix, KwaZulu Natal,South Africa) for assessment of non valvular Atrial fibrillation or valve 
prosthesis and treatment with Warfarin. 
 
Study Period: 
Patients who attendthe Gandhi Memorial Hospital, Adult Medical Outpatients Department from 
1
st
October 2015 to 30
th
 November 2015 will be randomly selected. 
Data will be analysed and interpreted during the period of December 2015 to February 2016. 
 
Limitations to the Study: 
The main limitation of this study is that is based on a retrospective cohort of patients in a single 
centre. 
The data studied here did not reflect any INR levels taken at other hospitals or during hospitalisations. 
The study period under review spanned 12 months and this may not necessarily be a long enough 
period to observe all INR findings. 
The size of the population group is limited to 150 and 100 patients for non valvular AF and valve 








Literature reviewed in this study has been referenced using the EndNote system. 
The study is a retrospective chart audit which seeks to maintain anonymity of the patients throughout 
the study. 
At no point will any of the patients’ charts be removed from the hospital premises nor will any 
duplication of charts or any part thereof be undertaken. No adjustments or amendments will be 
performed on any of the charts used. Furthermore patients will be randomised to a study population 
number and no publication of any patient names, clinician names or hospital or file numbers will take 
place. 
Any chart audit undertaken will be done so after the patient has completed his visit so as to not delay 
any patients’ visit nor disrupt any workings of the department. 
At no point will any patient or clinician interviews nor interventions take place. 
I will attempt to seek consent from the Department of Health, Kwa Zulu Natal and the Hospital 
Medical Manager (see Addendum 1) in order to proceed with the proposed study. 
This research will attempt at all times to remain impartial, true to findings and independant. There is 



















In order to ascertain permission for sampling from the proposed site, I have written a formal request 
addressed to the Medical Manager of the Hospital. (Addendum 1) 
Mahatma Gandhi Memorial Hospital 
100 Phoenix Highway 
Phoenix 
 
To the Medical Manager 
  
Re: Request for permission to conduct a study at your institution 
 
I am currently within the employ of the Department of Health-Kwazulu Natal. In addition I am presently 
enrolled in a postgraduate registrar training program at the University of Kwazulu Natal. 
I wish to conduct a retrospective and observational study on patients who attend the Adult Medical 
Outpatients Department at Mahatma Gandhi Memorial Hospital for the purposes of an MMED. 
The proposed research topic is titled Warfarin: Time in Therapeutic Range (TTR), A single centre 
retrospective study on patients using Warfarin for stroke prevention in non-valvular Atrial Fibrillation or 
for patients with Prosthetic heart valves. 
The aim of the study is to assess the quality of anticoagulation of patients on Warfarin for stroke 
prevention in non-valvular Atrial Fibrillation or in the presence of prosthetic heart valves. 
The indentified study population are patients attending Mahatma Gandhi Memorial Hospital, Adult 
Outpatients Department for assessment and treatment of non valvular Atrial Fibrillation and valve 
prosthesis. The study sample and the sample size will include patients who attend during October 
2015 and November 2015 and will be randomised into two cohorts of 150 Patients with non-valvular 
Atrial Fibrillation and on oral anticoagulants and 100 Patients with valve prosthesis and on oral 
anticoagulants. 
Once the sample cohorts are determined (by indication for anticoagulation), retrospective chart 
reviews will be undertaken to determine the following parameters for each patient: 
1. Age 
2. Gender 
3. Patient Risk Factors (in the case of valve prosthesis) which is Mitral, tricuspid or pulmonary 
position; Previous arterial thrombo-embolism; Atrial fibrillation; Left atrium diameter >50 mm; 
Mitral stenosis of any degree; Left ventricular ejection fraction <35%; Left atrial dense 
spontaneous echo contrast 
4. Prosthetic valve Thrombogenicity ( in the case of valve prostheses patients) 
5. INR values for the previous 1 year or least 12 values whichever is the longer 
6. Number of visits in the period determined  




8. Documented adverse event (any period while on anticoagulation) which includes any 
haemorrhage, any admission for Warfarin toxicity, any systemic embolism, any obstructed 
valve 
This data will then be collected and distributed in table format for each patient for the purposes of the 
study. 
I propose access to the study population by using the Medical outpatient department list of patients 
who are having INRs sampled for the day. 
At no point will any of the patients’ charts be removed from the hospital premises nor will any 
duplication of charts or any part thereof be undertaken. No adjustments or amendments will be 
performed on any of the charts used. Furthermore patients will be randomised to a study population 
number and no publication of any patient names, clinician names or hospital or file numbers will take 
place. 
Any chart audit undertaken will be done so after the patient has completed his visit so as to not delay 
any patients’ visit nor disrupt any workings of the department. 
At no point will any patient or clinician interviews take place. 
The perceived outcomes of the study will hold benefit to the patients attending the hospital and may 
have implications on future best practices. The results of the study will be made available to you upon 
your request. 
I will gladly consent to any signings required for the responsibility of the chart while I am utilising it. 
  
I have applied to seek Ethics approval for this study. 
I am at all times being supervised during this study. 
  
In order to continue this study, permission from the institute is required and I therefore request 
permission to undertake this study for the purposes described at this institution. 











ANNEXURE F: PLOTS OF QUANTITATIVE DATA 
































Normal Q-Q Plot : Valve cohort   (n=81)  Using Blom‟s fractional Rank estimation method 
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